

**777363 – DRIVE**

**Development of Robust and Innovative Vaccine Effectiveness**

**WP7 - IVE studies**

# Brand-specific influenza vaccine effectiveness in Europe Statistical Analysis Plan Season 2021/22

<b>Lead contributor</b>	Jorne Bicler (3 - P95)
<b>Other contributors</b>	Anke Stuurman (3 - P95)
	Antonio Carmona (FISABIO)
<b>Reviewers</b>	Ulrike Baum (THL)
	Anca Cristina Drăgănescu (NIID)
	Oana Săndulescu (NIID)
	Zineb Lesieur, Alexandre Descamps, Christine Durier (I-REIVAC)
	Roberto Bonaiuti (4 - UNIFI)
	Miriam Levi (4- UNIFI/USL TOSCANA CENTRO)

## Document History

Version	Date	Description
V1.0	17 JAN 2022	First Draft, JB and AS adapted the 2020/21 SAP and AC collected site information
V2.0	18 FEB 2022	Second draft, including comments from WP7 and DRIVE sites, input from DRIVE confounder study, and feedback from EFPIA/WP7 brainstorming discussion
V3.0	08 APR 2022	Third draft, including comments from EFPIA and ISC

# 1 Table of Contents

1	Table of Contents .....	2
2	Background .....	7
3	Reference Documents .....	7
4	Objectives .....	8
4.1	Primary objective .....	8
4.2	Secondary objectives .....	8
5	Study design .....	8
5.1	Participating study sites .....	8
6	Study population .....	20
7	Study Period .....	21
8	Case definitions .....	21
8.1	Influenza-like illness (ILI) .....	21
8.2	Severe acute respiratory infection (SARI) .....	22
8.3	Adherence to the case definitions .....	22
9	In- and exclusion criteria .....	23
9.1	Test-negative design studies .....	23
9.1.1	Recommended exclusion criteria .....	23
9.1.2	Adherence to the recommended ILI/SARI exclusion criteria .....	23
9.2	Cohort Studies .....	27
9.2.1	THL Finland: register-based cohort study .....	27
10	Outcome .....	27
10.1	Outcome definition .....	27
10.2	Swab sampling strategy .....	27
10.3	Laboratory testing .....	30
11	Exposure .....	30
11.1	Exposure definition .....	30
11.2	Source of exposure information .....	30
11.3	Expected influenza vaccine brands .....	31
12	Matching of cases and controls .....	33
13	Covariates .....	33
13.1	Age .....	36
13.2	Sex .....	36
13.3	Date at symptom onset/calendar time .....	36
13.4	Chronic conditions .....	36
13.5	Number of hospitalizations .....	38
13.6	Number of primary care consultations .....	38

13.7	SARS-CoV-2 status in the last 12 months .....	38
13.8	SARS-CoV-2 status at the time of swab .....	38
13.9	COVID-19 vaccination status .....	38
14	Data management .....	39
14.1	Data pre-processing at the site level .....	39
14.2	Data transfer .....	39
14.3	Central data storage .....	40
14.4	Data quality .....	40
15	Sample size considerations .....	41
15.1	General sample size considerations .....	41
15.2	Sample size considerations in the 2021/22 season .....	43
16	Statistical analysis .....	45
16.1	Descriptive analyses not directly related to the IVE analyses .....	45
16.2	Site-specific analysis: test-negative design studies .....	45
16.2.1	Attrition diagram .....	45
16.2.2	Descriptive analysis .....	46
16.2.3	Influenza vaccine effectiveness estimation .....	46
16.2.4	Sensitivity analysis .....	47
16.3	Site-specific analysis: cohort study .....	47
16.3.1	Attrition diagram .....	47
16.3.2	Descriptive analysis .....	47
16.3.3	Influenza vaccine effectiveness estimation .....	48
16.3.4	Sensitivity analysis .....	48
16.4	Pooled analysis .....	48
16.4.1	Descriptive analysis .....	49
16.4.2	Inclusion of influenza vaccine effectiveness estimates .....	49
16.4.3	Meta-analysis .....	49
16.4.4	Quantifying between-study heterogeneity .....	50
16.4.5	Outlier and influence analysis, and exploring reasons for potential outlying studies ..	50
16.4.6	Sensitivity analysis .....	50
17	Presentation of results .....	51
18	Software .....	51
19	Limitations .....	51
20	Quality control procedures .....	52
20.1	Documentation .....	52
20.2	Record retention .....	52
20.3	Data analysis and results .....	52
20.4	Monitoring of quality .....	52

777363 – DRIVE – D3.3

21	Ethics considerations.....	53
21.1	Ethics Approval .....	53
21.2	Informed consent .....	53
22	References .....	54
23	ANNEX 1: Study team .....	55

## List of abbreviations

aTIV	Adjuvanted trivalent influenza vaccine
BIVE	Italian Hospital Network
BMI	Body mass index
CI	Confidence interval
CIRI-IT	Centro Interuniversitario di Ricerca sull'Influenza e sulle altre infezioni trasmissibili
COVID-19	Coronavirus disease 2019
DRIVE	Development of Robust and Innovative Vaccine Effectiveness
DRIVE ESSA	DRIVE Electronic Study Support Application
DRIVE QCAC	DRIVE Quality Control and Audit Committee
ECDC	European Centre for Disease Prevention and Control
EL	Embætti landlæknis
EMA	European Medicines Agency
F-CRIN	French clinical research infrastructure network
FISABIO	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
GP	General Practitioner
GPP	Good Participatory Practice
GTPUH	Germans Trias I Pujol University Hospital
HCW	Healthcare worker
HUS	Helsinki University Hospital
ILI	Influenza like illness
IMI	Innovative Medicines Initiative
INSERM	Institut National de la Santé et de la Recherche Médicale
I-REIVAC	Innovative clinical research network in vaccinology
ISS	Istituto Superiore di Sanità
IVE	Influenza vaccine effectiveness
LAIV	Live-attenuated influenza vaccine
LCI	Laboratory-confirmed influenza
LPUH	La Paz University Hospital
MUV	Medical University Vienna
NIID	National Institute for Infectious Diseases "Prof. Dr. Matei Bals"
NVR	National Vaccination Register
OR	Odds ratio
PCR	Polymerase chain reaction
PC	Primary care
QIV	Non-adjuvanted quadrivalent influenza vaccine
QIVe	Quadrivalent inactivated egg-based influenza vaccine
QIVc	Quadrivalent inactivated cell-based influenza vaccine
QIVa	Quadrivalent adjuvanted influenza vaccine
RCGPRSC-OX	Royal College of General Practitioners / Research and Surveillance Centre / Oxford University
RE MA	Random-effects meta-analysis
REML	Restricted maximum likelihood
RJCUH	Hospital Universitario Rey Juan Carlos
RR	Relative risk
RT-PCR	Reverse transcription polymerase chain reaction
SAP	Statistical Analysis Plan
SARI	Severe acute respiratory infection
SARS-CoV2	Severe acute respiratory syndrome coronavirus 2
SUH	Hospital Universitario de Salamanca

777363 – DRIVE – D3.3

HUJT	Hospital Universitari de Girona Doctor Josep Trueta
THL	The Finnish Institute for Health and Welfare
TIV	Non-adjuvanted trivalent influenza vaccine
TIV-HD	High-dose trivalent influenza vaccine
TND	Test negative design
UNIS	University of Surrey
UK	United Kingdom
URTI	Upper respiratory tract infections
VE	Vaccine effectiveness
HUVH	Vall d'Hebron University Hospital
WHO	World Health Organization

## 2 Background

The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public-private partnership aiming to build capacity in Europe for estimating brand-specific influenza vaccine effectiveness (IVE). The DRIVE Project, which is funded by the Innovative Medicines Initiative (IMI), was initiated as a response to the changes for licensing of influenza vaccines in Europe. The new guidance on influenza vaccines by the European Medicines Agency (EMA) came into effect in the beginning of 2017. This guidance states that the performance of influenza vaccines should no longer be assessed based on serological assays, but should be based on post-authorization effectiveness studies [1].

In DRIVE, data from several independently operating national or regional study sites will be analyzed jointly to obtain sufficient geographical coverage and sample size for brand-specific IVE estimates. The main objective of DRIVE is to establish a sustainable network to estimate brand-specific seasonal IVE in Europe. The DRIVE network is expanding over the course of the project, and not all vaccine brands used in Europe are likely to be covered during the expansion phase of DRIVE.

In 2017/18, a pilot study was performed to test the different operational aspects of the DRIVE project, including the IT infrastructure, the DRIVE governance for conducting IVE studies, and to streamline key processes such as data collection, statistical analyses, and dissemination of study results [2]. In the pilot study, there were four test-negative design studies (TND) and one register-based cohort study. The DRIVE network is continuously expanding. The 2018/19 season was based on a multi-center study with data available from five primary care-based TND studies, six hospital-based TND studies, one register-based cohort, and two clinical cohorts (in pregnant women and their young infants and in healthcare workers). For the 2019/20, 2020/21 and 2021/22 seasons, the DRIVE network included 13 TND studies and one register-based cohort study. Due to the low levels of influenza virus circulation in the 2020/21 season, a minimal threshold in terms of number of cases was defined to conduct IVE analyses for the TND studies.

This Statistical Analysis Plan (SAP) describes the characteristics of the participating study sites, the site-specific statistical analysis as well as the statistical analysis to pool data across study sites for the 2021/22 influenza season.

As of the start of February 2022, the circulation of influenza in Europe has remained low or at interseasonal levels [3]. The most likely explanation for this is that non-pharmaceutical interventions used to limit COVID-19 spread also reduces the spread of influenza within Europe. As it is expected that some of these measures will remain in place for the rest of the 2020/21 season it seems plausible that the influenza circulation will remain very low during the remainder of the 2020/21 season. This poses a major challenge to DRIVE as it implies that the data necessary for performing some of the planned analyses will not be available.

## 3 Reference Documents

The SAP has been developed in companion to the following document:

- DRIVE Mock Report Season 2021/22.

The SAP has been developed using the following documents:

- DRIVE Generic protocols (D7.1.2 and D7.2).
- DRIVE 2021/22 local study protocols.
- DRIVE Generic SAP: combining information on Influenza Vaccine Effectiveness across study sites (D4.4).

- DRIVE data management plan (D4.2).

The following supplementary files are provided:

- Study team members (ANNEX 1).
- DRIVE minimal data requirements (ANNEX 2).

## 4 Objectives

### 4.1 Primary objective

To estimate confounder-adjusted seasonal **overall** and **brand-specific** IVE against laboratory-confirmed influenza stratified by setting (primary care, hospital-based or mixed setting in case the source of the cases cannot be obtained) and age group (6m-17yr, 18-64yr,  $\geq 65$ yr), by type of outcome:

- any laboratory-confirmed influenza;
- laboratory-confirmed influenza A, overall and by subtype (A(H1N1), A(H3N2));
- laboratory-confirmed influenza B, overall, and by lineage (B Victoria, B Yamagata).

### 4.2 Secondary objectives

To estimate confounder-adjusted seasonal **vaccine-type** IVE against laboratory-confirmed influenza stratified by setting (primary care, hospital-based or mixed) and age group (6m-17yr, 18-64yr,  $\geq 65$ yr), by type of outcome:

- any laboratory-confirmed influenza;
- laboratory-confirmed influenza A, overall and by subtype (A(H1N1), A(H3N2));
- laboratory-confirmed influenza B, overall, and by lineage (B Victoria, B Yamagata).

The following vaccine types will be considered:

- Adjuvanted TIV (aTIV)
- adjuvanted QIV (aQIV)
- high-dose QIV (hdQIV)
- live attenuated quadrivalent egg-based vaccine (LAIV)
- quadrivalent inactivated egg-based vaccine (QIVe)
- quadrivalent inactivated cell-based vaccine (QIVc)
- quadrivalent inactivated recombinant vaccine (QIVr)
- trivalent inactivated vaccine (TIV)

## 5 Study design

A multi-center study with data available from four primary care-based TND studies, nine hospital-based TND studies, and one register-based cohort.

### 5.1 Participating study sites

A list of the participating study sites according to study design and setting and their respective national



or regional influenza surveillance systems are given in Table 1. All the TND studies and the register-based cohort follow closely the DRIVE generic protocols (D7.1 and D7.2) for their respective study designs. Key characteristics of the TND studies and the register-based cohort study are summarized in Figure 1 and presented in more detail in Table 2-Table 3 for the TND studies and Table 4 for the register-based cohort study. More details on the individual studies are provided in the subsequent sections. When feasible, additional site-specific studies might be included in the analysis if test data are made available prior to 15th April 2021.

*Table 1. Overview of the participating study-sites, 2021/22*

Type of study, setting, country:			Influenza surveillance systems
<b>Test-negative design studies, primary care:</b>			
1.	Austria	Medical University Vienna (MUV), Austria	Diagnostic Influenza Network Austria, DINÖ
2.	Iceland	Directorate of Health - Embætti landlæknis (ELGP)	National Icelandic influenza surveillance system
3.	Italy	Istituto Superiore di Sanità (ISS)	National sentinel influenza surveillance system, INFLUNET
4.	United Kingdom	Royal College of General Practitioners Research and Surveillance Centre (RCGPRSC) & University of Oxford (OX)	English sentinel surveillance network, Point of Care Testing subset (12 general practices)
<b>Test-negative design studies, hospital based:</b>			
1.	France	Innovative clinical research network in vaccinology (I-REIVAC INSERM)	National surveillance of influenza vaccine effectiveness
2.	Iceland	Directorate of Health - Embætti landlæknis (ELHOSP)	National Icelandic influenza surveillance system – Reykjavik Hospital
3.	Italy	Centro Interuniversitario di Ricerca sull’Influenza e sulle altre infezioni trasmissibili Italian Hospital Network (CIRI-IT BIVE)	n/a
4.	Romania	National Institute for Infectious Disease “Prof. Dr. Matei Balș”, Bucharest	n/a
5.	Spain	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)	Valencia Hospital Network for the Study of Influenza and Other Respiratory Viruses, VAHNSI
6.	Spain	Germans Trias i Pujol University Hospital (GTPUH), Badalona	Information Plan for Acute Respiratory Infections in Catalonia, PIRIDAC
7.	Spain	Hospital Universitario La Paz (LPUH), Madrid	n/a
8.	Spain	Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain & Hospital Universitari de Girona Doctor Josep Trueta (HUGJT), Girona	Information Plan for Acute Respiratory Infections in Catalonia, PIRIDAC
9.	Spain	Hospital Universitario de Salamanca (SUH)	n/a
<b>Register-based cohort study</b>			
1.	Finland	The Finnish Institute for Health and Welfare (THL)	Online surveillance of influenza vaccine effectiveness

Setting		6m-17y	18-64y	65+y	Sampling strategy	Study design	
	Primary care	MUV (Austria)			<div></div>	Predefined rules or recommendations  All  At clinician's discretion	TND
		ISS (Italy)		<div></div>			
		ISS (Italy)		<div></div>			
		EL GP (Iceland)		<div></div>			
		RCGP RSC OX (UK)		<div></div>			
	Hospital	EL HOSP (Iceland)			<div></div>	All	
		CIRI-IT BIVE (Italy)			<div></div>		
		HUVH & HUJT (Spain)			<div></div>		
		GTPUH (Spain)			<div></div>		
		INSERM (France)		<div></div>			
		SUH (Spain)		<div></div>			
		LPUH (Spain)		<div></div>			
NIID [COVID-19 hospital] (Romania)			<div></div>				
<div></div>		FISABIO (Spain)		<div></div>			
Mixed	<div></div>	THL (Finland)		<div></div>	At clinician's discretion	Register-based cohort	
Hospital	<div></div>	THL (Finland)		<div></div>			

Legend	Case definitions	Laboratory tests for influenza
	ILI (ECDC)	RT-PCR
	ILI (sudden onset fever, respiratory symptoms, myalgia)	RT-PCR and/or antigen detection
	SARI (IMOVE+ 2017/18)	
	Hospitalization for any acute reason with onset of symptoms leading to hospitalization in the 7 days prior to admission	
	SARI (IMOVE+ 2017/18 without general deterioration, considering only symptoms at admission)	
	Laboratory-confirmed influenza	

Figure 1. Overview of study characteristics, TND and register-based cohort, 2021/22.

Table 2. Overview of test-negative design study sites characteristics, primary care – 2021/22

Site Country	MUV Austria	ELGP Iceland	ISS Italy	RCGPRSC-OX United Kingdom
<b>Setting</b>	Primary care	Primary care	Primary care	Primary care
<b>Source of cases</b>	165 primary care physicians	Ca. 200 (all primary care practices in Iceland)	Ca. 245 primary care physicians	Around 450 primary care practices
<b>Population</b>	General population ≥6 months	All ages	General population ≥6 months	All ages
<b>Cases</b>				
Case definition	ILI <sup>(1)</sup>	ILI <sup>(1)</sup> -URTI	ILI <sup>(1)</sup>	ILI <sup>(1)</sup>
Influenza cases	ILI + LCI	ILI-URTI + LCI	ILI + LCI	ILI + LCI
Case identification	During consultation	During consultation, From hospital or Primary care database or register	During consultation	During consultation
<b>Matched controls</b>	No	No	No	No
<b>Sampling strategy<sup>(3)</sup></b>	All / Predefined rules At physician's discretion	At physician's discretion Any URTI or GE symptoms	<65y: Recommendations formulated 65y+: All	All ILI patients
<b>Swab</b>				
Type of swab	Nasopharyngeal	Nasopharyngeal	Throat or nasopharyngeal swab	Nasal
<b>Laboratory testing</b>				
Laboratory test influenza	For all samples: RT-PCR Antigen testing Viral growth in cell culture Antigenic characterization For 20% of samples: Sequencing of H and N, For 30-100 samples whole genome sequencing	RT-PCR	RT-PCR	RT-PCR
A/subtype available	Yes	Yes	Yes	Yes
B/lineage available	Yes	Yes	Yes	Yes

Site Country	MUV Austria	ELGP Iceland	ISS Italy	RCGPRSC-OX United Kingdom
Laboratory test subtyping	RT-PCR	RT-PCR	RT-PCR	RT-PCR
<b>Data sources</b>				
Case definition	Primary data collection	Secondary data (registers/medical records)	Primary data collection	Secondary data (GP medical records)
Vaccination status	-GP medical records -Patient/ relatives' interview (if ILI patient is not consulting their regular GP)	Vaccination registry (local/regional/national)	GP medical records	GP medical records Vaccination registry (local/regional/national)
Vaccine brand and date	GP medical records Vaccination card	Vaccination registry (local/regional/national)	GP medical records	GP medical record Vaccination registry (local/regional/national)
Baseline clinical data	Primary data collection	Secondary data (registers/medical records)	GP medical records	Secondary data (GP medical records)
<b>Obligatory* covariates available for adjustment</b>	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition	Age, sex, $\geq 1$ chronic condition
<b>Preferred** covariates available for adjustment</b>	Influenza vaccination in previous season, COVID-19 vaccination	Influenza vaccination in previous season, COVID-19 vaccination	N primary care visits in last 12 months, influenza vaccination in previous season,	N primary care visits in last 12 months, N hospitalizations in last 12 months, Influenza vaccination in previous season, COVID-19 vaccination
<b>Individual or aggregated data shared</b>	Individual	Individual	Individual	Individual

ILI: influenza-like illness; LCI: laboratory-confirmed influenza; HCW: healthcare worker; RT-PCR: Reverse transcription polymerase chain reaction, ICU: intensive care unit.

\* Covariates for which data collection is preferred (but not obligatory) according to the core protocol are: nr of primary care visits in last 12 months (for primary care studies), nr of hospitalizations in the last 12 months (for hospital studies), influenza vaccination in the previous seasons and COVID-19 vaccination. \*\*The mandatory covariates are age, sex, calendar time at symptom onset and presence of at least one chronic condition.

777363 – DRIVE – D3.3

(1) ECDC case definition, (2) WHO case definition: Sudden onset of fever, respiratory symptoms, and myalgia, (3) Sampling strategies: a) All: all patients with ILI or SARI are sampled; b) Predefined rules: systematic sampling according to predefined rules; c) At clinician's discretion: non-systematic sampling at practitioner's discretion

Table 3. Overview of test-negative design study sites characteristics, hospital – 2021/22 (part 1)

Site	I-REIVAC	CIRI-IT BIVE	ELHOSP
Country	France	Italy	Iceland
<b>Setting</b>	Hospital	Hospital	Hospital
<b>Source of cases</b>	5 hospitals	5 hospitals	1 hospital
<b>Population</b>	General population ≥18 years	General population ≥ 18 years	All ages
<b>Cases</b>			
Case definition	SARI <sup>(1)</sup>	SARI <sup>(1)</sup>	ILI <sup>(ECDC)</sup> - URTI
Influenza cases	SARI + LCI	SARI + LCI	ILI-URTI + LCI
Case identification	From hospital databases From hospitalized patients	From hospital databases	During consultation, From hospital or Primary care database or register (: if the respiratory sample is sent to the reference virology lab)
<b>Matched controls</b>	No	No	No
<b>Sampling strategy<sup>(4)</sup></b>	All	All	Any URTI or GE symptoms At physician's discretion (4 swabs per patient)
<b>Swab</b>			
Type of swab	Nasopharyngeal or bronchoalveolar lavage or tracheal aspiration	Nasal and throat or nasopharyngeal	Nasopharyngeal
<b>Laboratory testing</b>			
Laboratory test influenza	RT-PCR	RT-PCR	RT-PCR
A/subtype available	Yes	Yes	Yes
B/lineage available	Yes	Yes	Yes
Laboratory test subtyping	RT-PCR	RT-PCR or multiplex RT-PCR	RT-PCR
<b>Data sources</b>			
Case definition	-Primary data collection -Secondary data collection	Primary data collection Secondary data collection	Secondary data (registers/medical records)
Vaccination status	-Patient or relatives' interview -GP or pharmacists' interview -Vaccine card	-Medical records -Vaccination registry	Vaccination registry (local/regional/national)
Vaccine brand and date	-GP or pharmacists' interview (medical records) for those that reported being vaccinated -Vaccine card	-Medical records -Vaccination registry	Vaccination registry (local/regional/national)

Site Country	I-REIVAC France	CIRI-IT BIVE Italy	ELHOSP Iceland
Baseline clinical data	Primary data collection Secondary data collection	Primary data collection Secondary data collection	Secondary data (registers/medical records)
<b>Obligatory* covariates available for adjustment</b>	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition	Age, sex, calendar time at symptom onset, $\geq 1$ chronic condition
<b>Preferred** covariates available for adjustment</b>	N hospitalizations in last 12 months, influenza vaccination in previous season (two), COVID-19 vaccination	N hospitalizations in last 12 months, COVID-19 vaccination	Influenza vaccination in previous season, COVID-19 vaccination
<b>Individual-level or aggregate data shared</b>	Individual	Individual	Individual

H: hemagglutinin; ICU: intensive care unit; ILI: influenza-like illness; LCI: laboratory-confirmed influenza; HCW: healthcare worker; RT-PCR: Reverse transcription polymerase chain reaction. SARI: severe acute respiratory infection, URTI: upper respiratory tract infection.

\* Covariates for which data collection is preferred (but not obligatory) according to the core protocol are: nr of primary care visits in last 12 months (for primary care studies) ,nr of hospitalizations in the last 12 months (for hospital studies), influenza vaccination in the previous seasons and COVID-19 vaccination. \*\*The obligatory covariates are age, sex, calendar time at symptom onset and presence of at least one chronic condition.

(1) IMOVE+ 2017/2018 case definition. (2) With symptom onset in the 7 days prior to admission (3) modified SARI case definition, in which only symptoms before admission are considered, “deterioration of general condition” is not considered, symptom onset in the 7 days prior to admission. (4) Sampling strategies 1) all: all patients with ILI or SARI are sampled; 2) ‘predefined rules/recommendations’: systematic sampling according to predefined rules or recommendations; 3) ‘undefined’: non-systematic sampling, (5) in the LPUH study both ILI and SARI cases are sampled, in the DRIVE analysis only the SARI will be included. (6) in the 2021/22 season, the NIID hospital is dedicated to COVID-19 infections and (nearly) all LCI cases will be expected to be co-infections.

Table 3. Overview of test-negative design study sites characteristics, hospital – 2021/22 (part 2)

Site Country	NIID Romania	FISABIO Spain	GTPUH Spain
<b>Setting</b>	Hospital <sup>(6)</sup>	Hospital	Hospital
<b>Source of cases</b>	1 hospital	4 hospitals	1 hospital
<b>Population</b>	General population $\geq 6$ months	General population $\geq 6$ months	General population $\geq 6$ months
<b>Cases</b>			
Case definition	SARI <sup>(1)</sup>	<5y: Hospitalized for any acute reason <sup>(2)</sup> $\geq 5y$ : modified SARI <sup>(3)</sup>	SARI <sup>(1)</sup>

Site Country	NIID Romania	FISABIO Spain	GTPUH Spain
Influenza cases	SARI + LCI	SARI <sup>(3)</sup> + LCI	SARI + LCI
Case identification	From hospitalized patients	From hospitalized patients	From laboratory (all those tested for influenza) and then hospital databases (to check if they fulfill SARI criteria)
<b>Matched controls</b>	No	No	No
<b>Sampling strategy<sup>(4)</sup></b>	All	All	All
<b>Swab</b>			
Type of swab	<14y: nasopharyngeal and nasal ≥14y: nasopharyngeal and pharyngeal	<14y: nasopharyngeal and nasal ≥14y: nasopharyngeal and pharyngeal	Nasopharyngeal
<b>Laboratory testing</b>			
Laboratory test influenza	RT-PCR	RT-PCR	< 18y: Antigen detection > 18y: PCR
A/subtype available	Yes	Yes	Yes
B/lineage available	Yes	Yes	Yes (sent to HUVH)
Laboratory test subtyping	RT-PCR	RT-PCR	sequencing
<b>Data sources</b>			
Case definition	-Primary data collection -Hospital medical records	Primary data collection	Hospital medical records
Vaccination status	-Vaccine card -Primary care physician interview -Hospital records -Patient /relatives interview	Vaccine register	Records of Catalan Institute of Health
Vaccine brand and date	-Vaccine card -Primary care physician interview -Hospital records -Patient /relatives interview	Vaccine register	Records of Catalan Institute of Health
Baseline clinical data	-Medical records -Patient /relatives interview -Interview with attending physician	-Medical records -Patient interview	-Medical records
<b>Obligatory* covariates available for adjustment</b>	Age, sex, calendar time at symptom onset, ≥1 chronic condition	Age, sex, calendar time at symptom onset, ≥1 chronic condition	Age, sex, calendar time at symptom onset, ≥1 chronic condition
<b>Preferred** covariates available for adjustment</b>	N hospitalizations in last 12 months, COVID-19 vaccination	N hospitalizations in last 12 months, COVID-19 vaccination	N hospitalizations in last 12 months, COVID-19 vaccination



Site Country	NIID Romania	FISABIO Spain	GTPUH Spain
<b>Individual-level or aggregate data shared</b>	Individual	Individual	Individual

H: hemagglutinin; ICU: intensive care unit; ILI: influenza-like illness; LCI: laboratory-confirmed influenza; HCW: healthcare worker; RT-PCR: Reverse transcription polymerase chain reaction. SARI: severe acute respiratory infection, PCR: polymerase chain reaction.

\* Covariates for which data collection is preferred (but not obligatory) according to the core protocol are: nr of primary care visits in last 12 months (for primary care studies) ,nr of hospitalizations in the last 12 months (for hospital studies), influenza vaccination in the previous seasons and COVID-19 vaccination. \*\*The obligatory covariates are age, sex, calendar time at symptom onset and presence of at least one chronic condition.

(1) IMOVE+ 2017/2018 case definition. (2) With symptom onset in the 7 days prior to admission (3) modified SARI case definition, in which only symptoms before admission are considered, "deterioration of general condition" is not considered, symptom onset in the 7 days prior to admission. (4) Sampling strategies 1) all: all patients with ILI or SARI are sampled; 2) 'predefined rules/recommendations': systematic sampling according to predefined rules or recommendations; 3) 'undefined': non-systematic sampling, (5) in the LPUH study both ILI and SARI cases are sampled, in the DRIVE analysis only the SARI will be included. (6) in the 2021/22 season, the NIID hospital is dedicated to COVID-19 infections and (nearly) all LCI cases will be expected to be co-infections.

Table 3. Overview of test-negative design study sites characteristics, hospital – 2021/22 (part 3)

Site Country	LPUH Spain	SUH Spain	HUVH & HUGJT Spain
<b>Setting</b>	Hospital	Hospital	Hospital
<b>Source of cases</b>	1 hospital	1 hospital	2 hospitals
<b>Population</b>	General population ≥14years	Adults 18-65y Elderly (65+)	General population ≥6 months
<b>Cases</b>			
Case definition	ILI <sup>(3)</sup> /SARI	SARI <sup>(1)</sup>	SARI <sup>(1)</sup>
Influenza cases	ILI/SARI <sup>(5)</sup> + LCI	SARI + LCI	SARI + LCI
Case identification	From Microbiology department (all those tested for Influenza.	From hospital or primary care database orFrom hospital database register and from emergency room	
<b>Matched controls</b>	No	No	No
<b>Sampling strategy<sup>(4)</sup></b>	All	All ILI/SARI patients	All
<b>Swab</b>			
Type of swab	Nasopharyngeal	Nasopharyngeal	< 18y: usually nasopharyngeal

			>18 y: nasopharyngeal and/or pharyngeal and/or bronchoalveolar
<b>Laboratory testing</b>			
Laboratory test influenza	RT-PCR	RT-PCR	< 18y: Antigen detection > 18y: PCR
A/subtype available	Yes	Yes	Yes
B/lineage available	Yes	No	Yes
Laboratory test subtyping	RT-PCR	PCR-based assays are usually used for the rapid (GeneXpert Flu/RSV) laboratory-confirmation of influenza in respiratory specimens from adults. In addition, a routine real-time multiplex PCR (Qiasat Respiratory Panel Assay (Quiagen)) is used for the laboratory-confirmation of influenza and other respiratory viruses in respiratory specimens. A specific real-time PCR assay is used for influenza A (H1pdm09/H3) subtyping of all detected viruses.	Sequencing
<b>Data sources</b>			
Case definition	Primary data collection Secondary data collection	Primary data collection (patient/next of kin interview)	Hospital medical records
Vaccination status	Electronic medical record and patient interview (incl vaccination through campaign or self-bought)	Vaccination registry (local/regional/national)	Records of Catalan Institute of Health
Vaccine brand and date	-_Electronic medical record and patient interview (incl vaccination through campaign or self-bought) -Primary care electronic health records -GP interview (medical records) -Pharmacy interview	-Vaccination registry (local/regional/national) -Vaccination card -Patient / next of kin	Records of Catalan Institute of Health
Baseline clinical data	-Medical records -Patient /relatives interview	Secondary data (registers/medical records)	-Medical records
<b>Obligatory* covariates</b>	Age, sex, calendar time at symptom	Age, sex, calendar time at symptom	Age, sex, calendar time at symptom

available for adjustment	onset, $\geq 1$ chronic condition	onset, $\geq 1$ chronic condition	onset, $\geq 1$ chronic condition
<b>Preferred** covariates available for adjustment</b>	N hospitalizations in last 12 months, COVID-19 vaccination	N hospitalizations in last 12 months, influenza vaccination in previous season (two), COVID-19 vaccination	N hospitalizations in last 12 months, COVID-19 vaccination
<b>Individual-level or aggregate data shared</b>	Individual	Individual	Individual

H: hemagglutinin; ICU: intensive care unit; ILI: influenza-like illness; LCI: laboratory-confirmed influenza; HCW: healthcare worker; RT-PCR: Reverse transcription polymerase chain reaction, SARI: severe acute respiratory infection, URTI: upper respiratory tract infection.

\* Covariates for which data collection is preferred (but not obligatory) according to the core protocol are: nr of primary care visits in last 12 months (for primary care studies) ,nr of hospitalizations in the last 12 months (for hospital studies), influenza vaccination in the previous seasons and COVID-19 vaccination. The obligatory covariates are age, sex, calendar time at symptom onset and presence of at least one chronic condition.

(1) IMOVE+ 2017/2018 case definition. (2) With symptom onset in the 7 days prior to admission (3) modified SARI case definition, in which only symptoms before admission are considered, “deterioration of general condition” is not considered, symptom onset in the 7 days prior to admission. (4) Sampling strategies 1) all: all patients with ILI or SARI are sampled; 2) ‘predefined rules/recommendations’: systematic sampling according to predefined rules or recommendations; 3) ‘undefined’: non-systematic sampling, (5) in the LPUH study both ILI and SARI cases are sampled, in the DRIVE analysis only the SARI will be included. (6) in the 2021/22 season, the NIID hospital is dedicated to COVID-19 infections and (nearly) all LCI cases will be expected to be co-infections.

Table 4. Overview of register-based cohort study, 2021/22

<b>Site</b>	<b>THL</b>
<b>Country</b>	Finland
<b>Setting</b>	Primary care and hospital
<b>Source of cases</b>	Any setting: All healthcare facilities in Finland Hospital setting: Care Register for Health Care
<b>Population</b>	General population 6-months-6 years and ≥65 years
<b>Population size</b>	~1,600,000
<b>Start data collection</b>	Ongoing
<b>Case</b>	Any setting: LCI positive Hospital setting: LCI positive + inpatient episode (≥24 hours) for any reason starting or ongoing on the day of laboratory-confirmation
<b>Sampling strategy<sup>(1)</sup></b>	undefined
<b>Type of swab</b>	Nasopharyngeal swabs or nasal and/or throat swabs or nasopharyngeal aspirates (sometimes other clinical samples) analyzed by real-time RT-PCR, multiplex RT-PCR, culture and/or antigen detection
<b>Who takes swab</b>	HCW
<b>Laboratory test influenza diagnosis</b>	RT-PCR, Antigen detection
<b>A/subtype available</b>	No
<b>B/lineage available</b>	No
<b>Laboratory test subtyping</b>	n/a
<b>Source of vaccination status</b>	National Vaccination Register
<b>Covariates available for adjustment</b>	Age, sex, calendar week, 1 chronic condition or more, number of hospitalizations in 2020, number of primary care consultations in the last 12 months before 04.10.2021

HCW: healthcare worker; LCI: laboratory-confirmed influenza; n/a: not applicable; RT-PCR: Reverse transcription-polymerase chain reaction,

(1) Sampling strategies 1) all: all patients with ILI or SARI are sampled; 2) 'predefined rules/recommendations': systematic sampling according to predefined rules or recommendations; 3) 'undefined': non-systematic sampling; 4) sampling recommendations

## 6 Study population

In all TND studies and the register-based study, the population under study is the general population. In the 2021/22 season, the NIID hospital is dedicated to the treatment of COVID-19, hence, for NIID the study population is the general population with a hospitalized COVID-19 infection; this site will be included in a sensitivity analysis only.

Table 5. Catchment population for studies in the general population, 2021/22.

Catchment population	
<b>TND primary care</b>	
Austria MUV	Ca. 1.5% of the population of Austria (8,859,000)
Iceland ELGP	100% of the population of Iceland (350 000 inhabitants)
Italy ISS	Ca. 0.8% of the population of Italy (60,360,000)
UK RCGPRSC-OX	Ca. 13 % of population England (7,200,000 out of 55,980,000 population in England)
<b>TND hospital</b>	
France I-REIVAC	Tertiary care university hospitals located in Paris (2 hospitals, population served: 1 620 000), Lyon (1 hospital, population 520 000), Rennes (1 hospital, population 220 000) and Montpellier (1 hospital, population 300 000)

Iceland ELHOSP	100% of the population of Iceland (340 000 inhabitants)
Italy CIRI-IT BIVE	Ca. 40% of the population of Italy. Tertiary care hospitals serving Siena province (population 250,000), Genoa metropolitan area (650,000), Rome (3,000,000) and Bari province (1,200,000), Milan city (1,350,000).
Romania NIID	Ca. 31% of the population of Romania (31,1%). Hospital serves Bucharest, Ilfov, Dambovita, Giurgiu, Prahova, Arges, Teleorman, Ialomita, Dolj, Valcea, Olt (catchment population 5,937,382)
Spain FISABIO	Hospitals serving part of Valencia region (1,008,000, 20% of Valencia region)
Spain GTPUH	Tertiary care university hospital serving a population of more than 250,000 inhabitants of Badalona, Sant Adrià de Besòs, and various municipalities of Maresme area. In addition, it is a referral hospital for more than 800,000 citizens of Barcelona province.
Spain LPUH	Tertiary care university hospital local in Madrid (serving a population of 800,000)
Spain HUVH & HUJT	HUVH has a primary catchment area of 430.000 inhabitants (secondary over 2 million) in the province of Barcelona and HUJT 156.000 in the province of Girona
Spain SUH	185,000 inhabitants
<b>Register-based cohort</b>	
Finland THL	99% of all children 6m-6y and 99.9% of all elderly 65-100y in Finland

## 7 Study Period

For the TND studies, the study period for the analysis will start when the influenza virus circulation begins (first week of two consecutive weeks when influenza viruses are detected at the study site level, based on the data as provided to DRIVE) in the country/region. The study period will finish after the influenza season (defined as the end of the week prior to the first of two consecutive weeks when no influenza viruses are detected at the study site level, based on the data as provided to DRIVE) or April 30<sup>th</sup> 2021, whichever will occur first. The study period of analysis might be different for different study sites.

In the particular case of THL (Finland), data are continuously collected throughout the year since the national registers are used. The study period for analysis goes from week 40 (October 4<sup>th</sup> 2021) till April 30<sup>th</sup>, 2022.

## 8 Case definitions

The case definitions used in the TND studies were influenza-like illness (ILI) and severe acute respiratory infection (SARI). ILI and SARI cases are identified among all patients presenting to primary care or hospital, respectively.

In Iceland, patient records for all patients presenting to general practice with an upper respiratory tract infection or to hospital for whom a sample was sent to the laboratory of the participating hospital were reviewed for ILI or SARI symptoms.

### 8.1 Influenza-like illness (ILI)

A case of ILI will be defined by the ECDC case definition [4] as an individual who presents with a:

- sudden onset of symptoms;

AND, at least one of the following four systemic symptoms:

- fever or feverishness;
- malaise;
- headache;
- myalgia;

AND, at least one of the following three respiratory symptoms:

- cough;
- sore throat;
- shortness of breath.

## 8.2 Severe acute respiratory infection (SARI)

A case of SARI will be defined by the IMOVE+ 2017/2018 case definition as a hospitalized person with a suspicion of a respiratory infection, with at least one of the following systemic symptoms or signs:

- fever or feverishness;
- malaise;
- headache;
- myalgia;
- deterioration of general condition (asthenia or loss of weight or anorexia or confusion or dizziness);

AND at least one respiratory symptom or sign e.g.:

- cough;
- sore throat;
- shortness of breath;

at admission or within 48 hours after admission.

The symptoms should not have started (or, if chronic, clearly worsened) more than 7 days before swabbing.

## 8.3 Adherence to the case definitions

All TND study sites follow the ILI or SARI clinical case definitions except for Spain FISABIO, where a modified SARI definition is used.

### FISABIO Spain (TND hospital-based)

For children <5 years, a clinical case is defined as a person with a hospitalization for any acute respiratory reason whose symptom onset (of any symptom possibly related to influenza: acute upper and lower respiratory disease; dyspnea breath anomaly shortness of breath, tachypnea; asthma; pneumonia and influenza; fever or fever unknown origin or non-specified; cough; apnea; COVID-19 or COVID-19 suspicion ) was in the 7 days prior to admission.

For subjects 5 years and above, a modified SARI case definition is used. More particularly, only symptoms before admission are considered, “deterioration of general condition” is not considered, and the symptoms could not start more than 7 days before the date of admission instead of the date of sampling.

## 9 In- and exclusion criteria

### 9.1 Test-negative design studies

#### 9.1.1 Recommended exclusion criteria

The following exclusion criteria will be applied to subjects presenting with ILI:

1. is unwilling to participate or unable to communicate and give consent (the consent may also be given by her/his legal representative, or by specific consent procedures, acceptable according to the local ethical review process);
2. is less than 6 months of age at the time of the onset of the symptoms;
3. has a contraindication for influenza vaccine;
4. is institutionalized at the time of symptoms onset;
5. will have the respiratory specimen taken  $\geq 8$  days after ILI onset;
6. tested positive for any influenza virus in the current season before the onset of symptoms leading to the current primary care visit/hospitalization.
7. is potentially vaccinated (positive vaccination status is based on recall alone and cannot be confirmed by registers or is otherwise ambiguous).
8. age not part of the brand-specific licensed age-indication (only applicable for vaccinated subjects)\*

The following exclusion criteria will be applied to subjects presenting with SARI:

1. is unwilling to participate or unable to communicate and give consent (the consent may also be given by her/his legal representative, or by specific consent procedures, acceptable according to the local ethical review process);
2. is less than 6 months of age at the time of the onset of the symptoms;
3. has a contraindication for influenza vaccine;
4. is institutionalized at the time of symptoms onset;
5. had the respiratory specimen taken  $\geq 8$  days after SARI onset;
6. tested positive for any influenza virus in the current season before the onset of symptoms leading to the current primary care visit/hospitalization;
7. was previously hospitalized  $< 48$  hours prior to SARI onset;
8. had his/her ILI/SARI onset  $\geq 48$  hours after hospital admission.
9. is potentially vaccinated (positive vaccination status is based on recall alone and cannot be confirmed by registers or is otherwise ambiguous).
10. age not part of the brand-specific licensed age-indication (only applicable for vaccinated subjects)\*

\*Note: as age at vaccination is not collected within DRIVE, the brand-specific age-indication criterium will be based on the age at onset.

#### 9.1.2 Adherence to the recommended ILI/SARI exclusion criteria

All variables related to the exclusion criteria are listed as obligatory variables in the Minimal Data Requirements (ANNEX 2). An overview of the adherence to the ILI and SARI exclusion criteria given in Table 7. Records that violate the exclusion criteria will be discarded either at the data transfer stage or at the central analysis stage, whenever possible.

At the UK RCGPRSC-OX site, date of symptom onset is expected to be systematically unavailable,

777363 – DRIVE – D3.3

prohibiting the application of the exclusion criterion “respiratory specimen taken  $\geq 8$  days after ILI/SARI onset”. Therefore, UK RSCGPRSC-OX will be excluded from the primary analysis. A sensitivity analysis in which data from UK RCGPRSC-OX will be included will be performed.



Table 7. Test-negative design studies: overview of exclusion criteria applied at study recruitment, 2021/22

Site	MUV	ELGP	ISS	RCGPRS C-OX	I-REIVAC	ELHOS	CIRI-IT BIVE	NIID	FISABIO	GTPUH	HUVH & HUJT	LPUH	SUH
Country	Austria	Iceland	Italy	UK	France	Iceland	Italy	Romania	Spain	Spain	Spain	Spain	Spain
Setting	PC	GP	PC	PC	HO	HO	HO	HO	HO	HO	HO	HO	HO
Clinical case definition	ILI	ILI	ILI	ILI	SARI	ILI	SARI	SARI	SARI <sup>(1)</sup>	SARI	SARI	SARI	SARI
1. Unwilling or unable to give consent	Yes (R)	N.a.	Yes (R)	Yes (R)	Yes (R)	N.a.	Yes (R)	Yes (R)	Yes (R)	N.a. <sup>(2)</sup>	N.a. <sup>(2)</sup>	Yes (R)	N.a.
2. Age <6 months at symptom onset	Yes (R)	Yes (R)	Yes (R)	Yes (R)	n/a	Yes (R)	Yes (R)	Yes (R)	Yes (A)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
3. Contraindication	No	Yes (R)	Yes (R)	Yes (A)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (A)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
4. Institutionalized	Yes (R)	Yes (R)	Yes (R)	Yes (A)	Yes (R) <sup>(3)</sup>	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
5. Respiratory specimen taken ≥ 8 days after ILI/SARI onset	Yes (R)	Yes (R)	Yes (R)	No (NA)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
6. Prior influenza infection in current season	Yes (R)	Yes (R)	Yes (R)	Yes (A)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (A)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
7. Previously hospitalized < 48 hours prior to SARI onset	n/a	Yes (R)	n/a	n/a	Yes (T)	Yes (R)	Yes (R)	Yes (R)	Yes (R) <sup>(4)</sup>	Yes (R)	Yes (R)	Yes (R)	Yes (R)
8. SARI onset ≥ 48 hours after hospital admission	n/a	Yes (R)	n/a	n/a	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)	Yes (R)
9. Potentially vaccinated	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)
10. Age not within age-indication (vaccinated)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)	Yes (A)

subjects only)														
Other local exclusion criteria	No	No	No	No	Yes (R) (5)	No	Yes (R) <sup>(6)</sup>	No	Yes (R) <sup>(7)</sup>	Yes (R) <sup>(8)</sup>	Yes (R) <sup>(8)</sup>	No	No	

ILI: influenza like illness; HO: hospital; N.a.: not applicable, PC: primary care; SARI: severe acute respiratory infection

(R) Exclusion criterion applied at the time of recruitment (T) Exclusion criterion applied at the time of data transfer. (A) Exclusion criterion applied at the time of analysis. (NA) Exclusion criterion exceptionally not applied. (1) Modified SARI case definition, in which only symptoms before admission are considered, “deterioration of general condition” is not considered. (2) No informed consent was required as no intervention required for the study fall outside the usual practice of the HUVH & HUJTGH and GTPUH during the influenza season. (3) Institutionalized patient without regular community interaction. (4) Patients hospitalized < 30 days from the current hospitalization are excluded. (5) Patients under guardianship with samples not collected as part of routine care are not included. (6) Remains in hospital for less than 24 hours. (7) Not residing in the hospital's catchment area for at least the previous 6 months; Remains in hospital for less than 24 hours. (8) A patient not belonging to the Institut Català de la Salut network.

## 9.2 Cohort Studies

### 9.2.1 THL Finland: register-based cohort study

In the Finnish register-based cohort study, all subjects belonging to the study population and contributing data to the study period (starting 2021, week 40) are included, with the following exclusion criterion applied:

- exclusion of subjects with presumably incomplete vaccination records in 2021/22 or 2020/21
- exclusion of FinFluHD trial participants

## 10 Outcome

### 10.1 Outcome definition

The outcome of interest is laboratory-confirmed influenza, using the following definitions:

Estimating seasonal overall, brand-specific, and type-specific IVE against **any** medically attended laboratory-confirmed **influenza** (stratified by healthcare setting and age group):

- Positive: any laboratory-confirmed influenza.
- Negative: no laboratory-confirmed influenza.

Estimating seasonal overall, brand-specific, and type-specific IVE against any medically attended laboratory-confirmed **influenza type, subtype, or lineage** (stratified by healthcare setting and age group):

- Positive: laboratory-confirmed influenza of the specific type, subtype, or lineage of interest.
- Negative: no laboratory-confirmed influenza.

At THL (Finland, register-based cohort study), only positive results of the influenza tests are available. Two outcomes will be considered.

- Laboratory-confirmed influenza irrespective of whether the sample was taken in primary care or the hospital setting, as recorded in the National Infectious Diseases Register
- Inpatient laboratory-confirmed influenza cases defined as laboratory-confirmed influenza cases hospitalized ( $\geq 24$  hours) for any reason starting or ongoing on the day of laboratory confirmation.

### 10.2 Swab sampling strategy

Different sampling strategies were used for collecting respiratory samples from patients meeting the ILI/SARI clinical case definitions:

- 'all': all patients with ILI or SARI are sampled;
- 'predefined rules/ sampling recommendations': systematic sampling according to predefined rules or recommendations for preferential sampling certain patients;
- 'undefined': non-systematic sampling at the practitioner's discretion.

All patients that met the case definition at TND hospital sites were swabbed. For the TND primary care studies, the sampling strategies are different for the different sites and might also differ between subpopulations from the same study site. In all sites, the subjects were tested for both influenza and COVID-19, and for most sites, this happened using the same swab. Details on the sampling strategies are

777363 – DRIVE – D3.3

given in Table 8.

Swabs are performed by healthcare workers (HCW) in all studies. The types of swabs are either nasal, nasopharyngeal, oropharyngeal, pharyngeal, or throat swabs (Table 2-Table 3). Samples taken  $\geq 8$  days after ILI onset will be excluded from all TND analyses.

Table 8. Test-negative design studies: overview of influenza and COVID-19 swab sampling strategies used, 2021/22.

Site	MUV	ELGP	ISS	RCGPRSC -OX	I-REIVAC	ELHOSP	CIRI-IT BIVE	NIID	FISABIO	GTPUH	HUVH & HUGJT	LPUH	SUH
<b>Country</b>	Austria	Iceland	Italy	UK	France	Iceland	Italy	Romania	Spain	Spain	Spain	Spain	Spain
<b>Setting</b>	PC	PC	PC	PC	HO	HO	HO	HO	HO	HO	HO	HO	HO
<b>Clinical case definition</b>	ILI	ILI	ILI	ILI	SARI	ILI & SARI	SARI	SARI	SARI <sup>(1)</sup>	SARI	SARI	ILI	SARI
<b>Sampling strategy</b>	Predefine d rule <sup>(2)</sup>	At the physician 's discretio n	Predefine d rule <sup>(3)</sup>	At the physician 's discretio n	All	At the physician 's discretio n	All	All	All	All	All	All	All
<b>Same swab used for COVID-19 and influenza test</b>	Yes	Yes	Yes	Yes	Yes <sup>(4)</sup>	Yes	Yes	Yes <sup>(5)</sup>	Yes	No	Yes	Yes	Yes
<b>Influenza and COVID-19 screening testing and triage</b>	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time	All subjects tested for both at same time

ILI: influenza-like illness; HO: hospital; n/a: not applicable, PC: primary care; SARI: severe acute respiratory infection, URTI: upper respiratory tract infection. (1) modified SARI case definition, in which only symptoms before admission are considered, "deterioration of general condition" is not considered, and for which the symptoms did not start more than 7 days before admission (2) All (up to 30 swabs/weeks), if more than 30 ILI patients per week then systematic sampling (depending on the number of ILI patients, every 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, etc). (3) Systematic sampling of the first 2 ILI patients that present each week, and if possible all ≥65years ILI cases. (4) For some patients, nasopharyngeal swabs or aspirates are first tested for COVID-19 and subsequently for influenza (if sufficient material remaining). (5) In case the patient is already confirmed with COVID-19 a separate swab for influenza will be taken. In the emergency department, the same swab can be used.

## 10.3 Laboratory testing

All TND sites used RT-PCR for laboratory confirmation of influenza (in the age groups of interest for DRIVE). Subtyping/lineage testing was done using PCR, real-time-PCR, or sequencing. Except for THL (Finland, register-based cohort), all sites are collecting information on influenza subtypes (A/H1N1, A/H3N2) and /lineages (B/Victoria, and B/Yamagata). An overview of the type of swabs and laboratory tests is given in (Table 2-Table 4).

## 11 Exposure

### 11.1 Exposure definition

The exposure definition has changed as compared what is stated in the core TND protocol. The previous definition was depended on vaccination information from the previous which is not consistently available among the different sites. The current definition should reflect the available data more closely.

An individual aged  $\geq 9$  years will be considered as

- **Vaccinated** with the influenza vaccine of interest if influenza vaccine was administered in the current season and  $>14$  days before ILI/SARI symptom onset
- **Unvaccinated** if no influenza vaccine was administered in the current season

A child aged  $<9$  years (for whom two doses are recommended if they have not previously received influenza vaccine) will be considered as

- **Vaccinated** with the influenza vaccine of interest if the last dose of influenza vaccine in the current season was administered  $>14$  days before ILI/SARI symptom onset
- **Unvaccinated** if no influenza vaccine was administered in the current season

Note 1: For cohort studies, vaccination status will be treated as a time-varying variable whereas, for the TND studies, vaccination status is a fixed variable.

Note 2: Children  $<9$  years for who received two doses will hence only be considered vaccinated 14 days after the second dose. In case the records shows that a child  $<9$  years only received one dose it is assumed that the child is vaccinated.

### 11.2 Source of exposure information

The sources to obtain information on the exposure status were either vaccine registers, medical records, or vaccination cards (see Table 2-Table 4). Patients for whom the vaccination status is based on recall only, not verified based on vaccination register, medical record, or vaccination card are considered 'potentially vaccinated', and will be discarded from analysis (see [Section 16.2.1](#)).

For all the TND studies in primary care, vaccination status, vaccine brand, and vaccination date are retrieved from the GP records.

- In Austria MUV, if the patient is not consulting his/her own GP, the information will be obtained by patient interview.
- In the UK most flu vaccines are given in primary care, with brand and batch number recorded in the computerised medical records. Notification of LAIV given at school, by employers and

community pharmacy may be less reliable and the notification often does not contain brand or batch information [5].

The way vaccination status, vaccine brand, and vaccination date are ascertained in the TND hospital studies varies.

- In Spain FISABIO, vaccination status, vaccine brand, and vaccination date are retrieved from the vaccine registry. Completing the vaccination registry is part of routine care in Valencia. The information is retrieved by FISABIO using unique identifiers.
- In Spain HUVH & HUJT and GTPUH, the information is retrieved from the electronic records of the Catalan Institute of Health (whose primary care centers serve 75,2% of the population of Catalonia).
- In Italy CIRI-IT BIVE, vaccination status is collected by study staff using medical records or vaccination registry or GPs registry.
- In France I-REIVAC, vaccination status is retrieved through patient or relatives' interview, GP or pharmacists' interview (medical record), or vaccine card. For the vaccine brand and vaccination date, patient's GP or pharmacist are contacted to retrieve information from their records.
- In Spain LPUH, vaccination status and vaccine brand are retrieved through electronic medical records. If the information is not available in the electronic medical records it is obtained by phone interview with the patient. If they were vaccinated through the campaign, it is assumed the brand recommended for the age group was used (i.e., Chiroflu for those <65yr and Chiromas for those ≥65yr). If the patient doesn't remember the vaccination date, the date will be ascertained by contacting the GP. If the vaccine is self-bought, the health center or pharmacy will be contacted for confirmation of the vaccine brand and vaccination date.
- In Romania NIID, the information is retrieved from one of multiple sources: the vaccination card, by contacting the patient's GP (in case they are part of a risk group), from hospital records (for patients with chronic conditions only, as they are sometimes vaccinated in the hospital). If the above is not available, the information will be retrieved through patient interview.
- In Finland THL, all information is retrieved from the National Vaccination Register.
- In Iceland EL, the information is retrieved from the vaccination registry
- In Spain SUH, the information is retrieved from one of multiple sources: the vaccination card, the vaccination registry, or through patient interview
- In Spain RJCUIH, the information on vaccination status is retrieved from the electronic clinical history from the hospital and primary care healthcare system of Madrid. In case no vaccination record is retrieved the subject is considered unvaccinated. The information on the vaccine brand is obtained from the vaccine providers to the different centers of the Public Health Agency of Madrid.

### 11.3 Expected influenza vaccine brands

The vaccine types and vaccine brands that are expected to be used in the study areas are summarized in Table 9.

Table 9. Expected vaccine brands and type – all studies, 2021/22.

		MUV	ISS	RCGPR SC-OX	I- REIVA C	CIRI-IT BIVE	NIID	FISABI O	HUVH	LPUH	GTPUH	EL	SUH	THL
	Approved age indication	Austria	Italy	UK	France	Italy	Roman ia	Spain	Spain	Spain	Spain	Iceland	Spain	Finlan d
<b>TIV brands</b>														
Sandovac/ Chiroflu / Agrippal	≥6m													
<b>QIVe brands</b>														
Fluarix Tetra/ Alpharix Tetra	≥6m	x	x			x								
Vaxigrip Tetra	≥6m	x	x	x	x	x	x		x	x	x	x	x	x
Influvac Tetra/ Influvac S														
Tetra/FluVaccinol Tetra/ Influenza vaccine Tetra MYL	≥6m	x	x	x	x	x	x	x	x		x			
<b>QIVc brands</b>														
Flucelvax Tetra	≥2y	x	x	x		x		x					x	
<b>QIVr brands</b>														
Supemtek	≥18y			x										
<b>QIV LAIV brands</b>														
Fluenz Tetra	2-17y	x		x			x							x
<b>aTIV brands</b>														
Fluad/ Chiomas	≥65y	x						x		x			x	
<b>aQIV</b>														
Fluad Tetra	≥65y		x	x		x			x		x			
<b>High dose QIV</b>														
Efluelda / Fluzone HD	≥60y	x	x			x		x	x		x			

aTIV: Trivalent adjuvanted; LAIV: Quadrivalent live attenuated; TIV: Trivalent non-adjuvanted; QIVc: cell-based quadrivalent inactivated; QIVe: egg-based quadrivalent inactivated.



## 12 Matching of cases and controls

No matching of controls to cases in the TND studies will be done.

## 13 Covariates

An overview of the covariates available from the different study sites is given in Table 10. The covariates age, sex, and disease onset time are mandatory. The covariates presence of at least one chronic condition, pregnancy, the number of GP consultations or hospitalizations in past 12 months, date of most recent positive SARS-COV-2 test in past 12 months, COVID-19 vaccination status, fever, headache, myalgia, fatigue/malaise, sudden onset of symptoms, cough, difficulty breathing, sore throat, deterioration of general condition are recommended to be collected.

Table 10. Data collected on obligatory and recommended covariates – all studies, 2021/22.

Site	MUV	ISS	RCGPR SC-OX	CIRI-IT BIVE	NIID	FISABI O	HUVH & HUJT	I- REIVAC	LPUH	GPTUH	EL	SUH	THL
Country	Austria	Italy	UK	Italy	Romani a	Spain	Spain	France	Spain	Spain	Iceland	Spain	Finland
Setting	PC	PC	PC	HO	HO	HO	HO	HO	HO	HO	HO	HO	PC+HO
<b>Mandatory</b>													
Age at symptom onset <sup>(1)</sup>	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes <sup>(2)</sup>
Sex	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Date of symptom onset	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
<b>Recommended</b>													
Presence of at least one chronic condition	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Number of hospitalizations in the last 12 months	No	Yes <sup>(3)</sup>	Yes	Yes <sup>(3)</sup>	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes <sup>(4)</sup>
Number of primary care consultations in the last 12 months	No	Yes	Yes	nm	nm	nm (Yes)	nm	nm (Yes)	nm	nm (Yes)	No	Yes	Yes <sup>(5)</sup>
Date of most recent positive SARS-COV-2 test in past 12 months	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Fever	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Headache	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Myalgia	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Fatigue/malaise	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Sudden onset of symptoms		No	No		Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Cough	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Difficulty breathing	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Sore throat	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No
Deterioration of general condition	Yes	No	No	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	No
COVID-19 vaccination status	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Influenza vaccination status in previous season	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

777363 – DRIVE – WP7 – SAP pooled analyses

HO: hospital; Nm: not recommended for the setting; PC: primary care

- (1) Age in months for children < 1 year, otherwise age in years
- (2) Age at season onset or cohort inclusion instead of at symptom onset
- (3) Number of hospitalizations for any of the chronic conditions of interest in the last 12 months
- (4) Number of hospitalizations in 2020
- (5) Number of primary care visits in the last 12 months before 04.10.2021. Likely to be an underestimate as private care visits are not counted; follow-up visits are not distinguished from new visits

## 13.1 Age

Age in years (months for children <1yr) at symptom onset. For the Finland THL cohort study, the age is defined at the start of the influenza season (e.g., at day 1 of week 40).

## 13.2 Sex

Male or female.

## 13.3 Date at symptom onset/calendar time

To adjust for the effect of time, the date at ILI/SARI symptom onset will be used for TND studies whereas calendar week will be used for cohort studies.

## 13.4 Chronic conditions

Chronic conditions will be defined as the presence of at least one chronic condition as not all study sites provide information on chronic conditions separately. The chronic conditions include obesity (BMI  $\geq 30$ ) but exclude smoking and pregnancy. The definitions of the chronic conditions are given in Table 11.

Table 11. Definitions of chronic conditions.

Condition	Definition
<b>Chronic liver disease</b>	Any of the following diagnostic codes (ICD-10)*: B18, K70-74, K75.0-75.1, K75.3-75.9, K76-77  INCLUDING: Alcoholic liver disease, Toxic liver disease, Hepatic failure, Chronic hepatitis (viral & other), Fibrosis and cirrhosis of liver, Other inflammatory liver diseases, Other diseases of liver  EXCLUDING: Clinically insignificant liver cysts
<b>Diabetes</b>	Any of the following diagnostic codes (ICD-10)*: E10-E14, O24  INCLUDING: Any form of diabetes, including sequelae & diabetes metilious in pregnancy
<b>Cardiovascular diseases</b>	Any of the following diagnostic codes (ICD-10)*: A52.0, B37.6, I01-02, I05-09, I11.0, I13.0, I13.2, I20-25, I26-28, I30-43, I44-46, I48, I49.0, I49.5, I50-52, I70-71, Q20-Q28  INCLUDING: all conditions of heart & large vessels that are chronic or likely to have chronic sequelae. Cardiovascular syphilis, endo-, myo- and pericarditis, rheumatic fever, chronic rheumatic heart diseases, congenital malformations, hypertensive (renal) diseases with heart failure, ischaemic heart diseases, diseases of pulmonary circulation, atherosclerosis, cardiomyopathies, most conduction disorders, heart failure, aortic aneurysms & dissection, other heart diseases and their complications.  EXCLUDING: uncomplicated hypertension, previous uncomplicated pulmonary embolism (with no lasting cardiac insufficiency), paroxysmal tachycardias, most cases of premature depolarization.

<b>Cancer</b>	<p>Any of the following diagnostic codes (ICD-10)*: C00-97, D37-48, Z85, Z92.3, Z92.6.</p> <p>INCLUDING: All malignant neoplasms (both solid and haematologic) with potential to metastasize, either in treatment, active follow-up, or &lt;5 years post curative treatment.</p> <p>EXCLUDING: Benign &amp; in situ neoplasms. Basal cell carcinomas. Any cancer previously treated with curative intent &amp; in complete remission for ≥5 years.</p>
<b>Immuno-deficiency or organ transplant</b>	<p>Any of the following diagnostic codes (ICD-10)*: B20-B24, D80-84, D89, Z94</p> <p>INCLUDING: HIV infections, immunodeficiencies &amp; organ transplants. or iatrogenic: ≥2week systemic treatment, in the 3 months preceding symptom onset, with any of the following: corticosteroid (≥20 mg prednisolone daily or equivalent), ciclosporin, tacrolimus, mycophenolate, methotrexate, azathioprine, TNF-α blockers and other biological or cytostatic drugs with immunosuppressive effect</p> <p>EXCLUDING: Disorders of the immune system which do not lead to immunosuppression (e.g. some autoimmune conditions).</p>

Table 12. Definitions of chronic conditions, continued

Condition	Definition
<b>Lung disease</b>	<p>Any of the following diagnostic codes (ICD-10)*: A15-16, A19, A31.0, B33.4, E84.0, J40-47, J60-70, J80-84, J85-86, J90-91, J92.9, J93-94, J95-99</p> <p>INCLUDING: TB (pulmonary, miliary but not that of other systems), atypical mycobacteria, cystic fibrosis, asthma, COPD, bronchiectasis and other chronic sequelae of infections, chronic lung diseases due to external agents, interstitial lung diseases, pleural diseases, respiratory failure.</p> <p>EXCLUDING: acute respiratory infections, lung cancer, diseases of pulmonary circulation, pleural plaques without asbestos, previous uncomplicated pneumothorax.</p>
<b>Anemia</b>	<p>Any of the following diagnostic codes (ICD-10)*: D50-D64 diagnosed before the onset of symptoms.</p> <p>EXCLUDING: coagulopathies, uncomplicated hypersplenism, hepato/splenomegaly (D65-69, D70-77, D80-84, D86, D89)</p>
<b>Renal disease</b>	<p>Any of the following diagnostic codes: (ICD-10)*: I12-13, M10.30, N00-19, N20.0, N25-27, N28.0, N28.9, Q63.9, Z90.5</p> <p>EXCLUDING: Clinically nonsignificant kidney cysts</p>
<b>Dementia</b>	<p>Any of the following diagnostic codes (ICD-10)*: F00-03, F05.1, G30-31</p> <p>EXCLUDING delirium w/o underlying dementia, hydrocephalus.</p>
<b>History of stroke</b>	<p>Any of the following diagnostic codes (ICD-10)*: I61-64, I67.8, I69, G93.1</p> <p>INCLUDING: both ischaemic and haemorrhagic strokes and anoxic brain damage. Also counting previous episodes and clear ischaemic findings seen in cranial imaging (even if fully recovered / no symptoms).</p>
<b>Rheumatologic diseases</b>	<p>Any of the following diagnostic codes (ICD-10)*: M05-09, M13, M30-36, M45</p> <p>INCLUDING rheumatoid diseases with presumed autoimmune origin and primarily musculoskeletal presentation.</p>

EXCLUDING: arthrosis, gout, scoliosis, infectious conditions etc.

**Obesity** BMI  $\geq 30$  or the diagnostic codes (ICD-10)\*: E66, E68

EXCLUDING: local adiposity and "other hyperalimentation" (=vitamin overdoses etc.)

BMI: body mass index; ICD: International classification of diseases.

\*or corresponding codes in other diagnostic coding systems.

### *Deviations from DRIVE Data Requirements*

For UK RCGPRSC-OX, a set of codes that matched with the UK's Chief Medical Officers' definition is used [6], which are similar to but not exactly the same as those in the DRIVE codebook.

## 13.5 Number of hospitalizations

The number of hospitalizations in the previous 12 months will be categorized as "0", "1 to 2" and "more than 2". The number of hospitalization is used as a proxy for the severity of chronic conditions.

For Finland THL, the number of hospitalizations refers to the number of hospitalizations in 2020.

## 13.6 Number of primary care consultations

The number of primary care consultations in the previous 12 months (not counting follow-up visits for the same cause) will be categorized as "0", "1 to 5" and "more than 5".

### *Deviations from DRIVE Data Requirements*

For Spain FISABIO and France I-REIVAC, only the number of primary care visits in the previous 3 months is available. For these two sites, this variable will be categorized as "0", "1 to 2" and "more than 2". This variable is used as a proxy for health care utilization.

For Finland THL, the number of primary care consultations is based on the number of consultations occurring before October 4<sup>th</sup>, 2021, additionally follow-up visits cannot be distinguished from new visits.

## 13.7 SARS-CoV-2 status in the last 12 months

In case the subject has had a positive COVID-19 test in the last 12 months, the date of the positive test is reported.

## 13.8 SARS-CoV-2 status at the time of swab

SARS-CoV-2 status at the time of ILI/SARI presentation, based on the swab taken to test for influenza.

## 13.9 COVID-19 vaccination status

COVID-19 vaccination status is recorded as "not vaccinated", "partially vaccinated" (1 dose of a two dose primary series), "fully vaccinated" (primary series), "primary course + booster".

Sites differ in how a single dose of Janssen COVID-19 vaccine is recorded. A single of Janssen COVID-19 vaccine is recorded as "partially vaccinated" at France IREIVAC, as "fully vaccinated" at Spain HUS, FISABIO, GTPUH, HUVH, LPUH, Austria MUV, Italy CIRI-IT and UK RCGPRSC-OX. At Romania NIID, before October 2021, a single dose is considered as "fully vaccinated"; between October 2021 and January 2022, a single dose is considered as "fully vaccinated" until 6 months after the date of

vaccination (and “partially vaccinated” thereafter); and as of January 17 2022 onwards as “fully vaccinated” until 4 months after the date of vaccination (and “partially vaccinated” thereafter). As information on vaccine brand is expected to be available for all sites, the majority of sites consider a single dose of Janssen as “fully vaccinated” and as this is consistent with the vaccine label, a single dose of Janssen will be considered as “fully vaccinated” for all sites.

## 14 Data management

### 14.1 Data pre-processing at the site level

The database custodians at the local sites are responsible to transform their data in the requested format and to subset to the requested population. Details will be available in the local study reports.

### 14.2 Data transfer

The study data will be uploaded by the DRIVE research study sites to the DRIVE Research server using the DRIVE Electronic Study Support Application (DRIVE ESSA), a password-protected web application. The data flow to the DRIVE Research server is described in Figure 2. The study data will be uploaded to the ESSA environment first. Upon uploading TND data to the ESSA Environment, data quality checks and visualisations are automatically generated and a list with data quality issues can be downloaded by the study site. As such, potential data quality issues can still be solved by the study site before transferring the data to the DRIVE Central Analysis Environment.

The DRIVE ESSA performs 7 different types of quality checks, related to compliance with minimal data requirements, the presence of duplicated records, variable formats and implausible values, inconsistencies between variables, and missing values. In addition to the quality checks, the DRIVE ESSA provides seven different data visualizations, summarizing the number of vaccinated subjects over time, the distribution of vaccine brands, the number of cases and controls over time, the age-gender pyramid, and the distribution of covariates (sex, age, number of hospitalizations during the last 12 months, and presence of at least 1 chronic condition) among cases and controls.

## DRIVE RESEARCH SERVER




Figure 2. DRIVE Electronic Study Support Application: data flow.

### 14.3 Central data storage

All data will be stored at the DRIVE Research server, which is a highly secured IT environment and network with strict rules for data access provided by P95. The general architecture of the DRIVE research server has three environments: the data import or ESSA Environment, the Central Analysis Environment, and the Output Environment. The DRIVE research server is only accessible through the secure file transfer protocol (with upload capability to the ESSA Environment and download capability out of the Output Environment) and the remote desktop protocol allowing data analysts/statisticians to log into the Central Analysis Environment. The transfer of any data between the different environments is done solely by the server administrator (or his back-up when needed) where data privacy assessments are carried out if deemed necessary. Every interaction on the DRIVE research server is logged, and these logs are accessible upon request.

### 14.4 Data quality

All data uploaded to the Central Analysis Environment will be checked for quality by the P95 team. The same types of quality checks will be performed as the ones automatically generated upon uploading TND data to the ESSA environment. When data quality issues are found, the data site responsible person will be contacted, and the data will either be corrected or discarded from further analysis. After performing the data quality checks and implementing the corrective measures, the study in/exclusion criteria will be applied and records with missing data in the outcome, exposure, and the obligatory covariate information will be discarded.

For every site separately, a data quality report will be produced. These reports will contain a description of the results of the quality checks performed, the amount of data that was retained for analysis after applying the in-and exclusion criteria, and graphical summaries of the retained data. The data quality report will be sent to the study site for approval.




## 15 Sample size considerations


### 15.1 General sample size considerations

The minimal detectable overall VE, i.e., the smallest VE that can be detected as significantly greater than zero, for a range of sample sizes for TND and cohort designs is given in Figure 2 and Table 12-Table 13. The calculations are performed assuming 80% power, two-sided 95% confidence levels, and overall vaccination coverages of 5%, 15%, 30%, and 50%. For TND studies, it is additionally assumed to have a 1:1 control per case allocation ratio. For the cohort studies, it is additionally assumed to have attack rates among the unvaccinated of 7% (reflective of the attack rate in adults) and 25% (reflective of the attack rate in children).


To estimate the overall IVE we generally recommend a minimum of 100 influenza-positive cases for TND studies and a minimum of 1000 subjects for cohort studies. As the optimal sample size strongly depends on the local vaccination coverage and brand distribution, site-specific sample size recommendations will be formulated as part of the network expansion and site selection. Sample sizes smaller than recommended are allowed as capacity building is an ongoing activity within the DRIVE project. A user-friendly web-application to perform sample size calculations for IVE studies has been developed and is available from <https://shinyproxy.p-95.com/app/drivesamplesize>.



Test-negative design



Cohort design (attack rate = 7%)



Cohort design (attack rate = 25%)

Figure 2. Minimal detectable overall Vaccine effectiveness (VE) for test-negative and cohort design studies, assuming 80% power, two-sided 95% confidence intervals and overall vaccination coverage of 5%, 15%, 30% and 50%. For the test-negative design, a 1:1 control per case allocation ratio is assumed. For the cohort design, attack rates of 7% and 25% are assumed.

Table 12. Minimum detectable overall Vaccine effectiveness (VE) for the test-negative design studies, assuming 80% power, two-sided 95% confidence intervals, a 1:1 control per case allocation ratio and overall vaccination coverage of 5%, 15%, 30% and 50%.

Number of cases	Minimum detectable VE			
	5% Coverage	15% Coverage	30% Coverage	50% Coverage
100	NA	79.35	63.16	55.98
200	91.57	61.58	48.67	43.44
500	65.35	42.45	33.35	30
750	55.49	35.64	27.95	25.22
1000	49.21	31.39	24.59	22.23

Table 13. Minimum detectable overall Vaccine effectiveness (VE) for cohort design studies, assuming 80% power, two-sided 95% confidence intervals, 7% and 25% attack rate in the unvaccinated and overall vaccination coverage of 5%, 15%, 30% and 50%.

Sample size	Attack rate %	Minimum detectable VE			
		5% Coverage	15% Coverage	30% Coverage	50% Coverage
500	7	87.66	76.69	71.29	73.16
1000	7	77.65	62.76	55.64	55.29
2000	7	65.64	49.38	42.2	40.96
3000	7	58.26	42.29	35.54	34.13
4000	7	53.09	37.69	31.35	29.92
500	25	66.20	49.12	41.46	39.80
1000	25	53.28	37.21	30.60	28.95
2000	25	41.21	27.56	22.27	20.85
3000	25	34.96	22.94	18.40	17.16
4000	25	30.96	20.10	16.05	14.93

## 15.2 Sample size considerations in the 2021/22 season

As the flu activity in the 2021/22 season will likely be influenced by measures taken to curb the spread of COVID-19 the number of influenza cases observed within the DRIVE network may be too small to conduct a meaningful vaccine effectiveness analysis. To prevent the use of resources on performing the analysis and writing the final report when it is likely that no statistically significant IVE estimate can be obtained, these activities will only be undertaken when a minimal number of influenza cases are observed in the dataset.

The number of influenza cases needed in a single TND study to reach a power of at least 50% or 80% to detect a crude IVE different from 0 was calculated for a range of study parameters. The calculations were performed for each combination of the following study parameters and the required number of influenza cases can be found in Table 14

1. Power of 50% or 80%
2. True IVE of 30% or 60%
3. Control:case ratio of 1, 2, or 4
4. Overall vaccination coverage among control subjects of 10%, 25%, or 60%

In DRIVE data from multiple TND studies is analyzed, however as this introduces extra heterogeneity the required number of influenza cases to reach the pre-specified power will be higher than the

numbers specified in Table 14.

*Table 14. Expected number of influenza cases required to reach a power of 50% for several combinations of the IVE, control:case ratio and overall vaccination coverage.*

IVE	Control:case ratio	Vaccination coverage among control subjects	Expected number of influenza cases required (Power = 50%)	Expected number of influenza cases required (Power = 80%)
30%	1	10%	781	1593
60%	1	10%	155	314
30%	2	10%	557	1171
60%	2	10%	102	223
30%	4	10%	445	959
60%	4	10%	75	176
30%	1	25%	357	727
60%	1	25%	66	134
30%	2	25%	259	538
60%	2	25%	45	96
30%	4	25%	209	443
60%	4	25%	34	77
30%	1	60%	246	502
60%	1	60%	38	77
30%	2	60%	186	377
60%	2	60%	29	57
30%	4	60%	156	315
60%	4	60%	24	47

For each combination of setting and age group, the control:case ratio and the vaccination coverage among the control subjects observed in the 2019/20 season was used to select the number of required influenza cases (Table 15). The required number of influenza cases was selected assuming an IVE of 60% as the required number of cases tended to be lower when an IVE of 30% was assumed and hence leads to a less stringent cut-off value. Additionally, the required number of influenza cases was based on the calculations assuming a power of 50%. In the design phase of studies (e.g. clinical trials), often a power of 80% (or even 90%) is required, however, within DRIVE the occurrence of non-significant estimates is not necessarily problematic and requiring a power of 80% would lead to more stringent cut-off values as compared to a power of 50%. Since the distribution of brands and therefore also the brand-specific coverage tends to vary more across seasons than the overall vaccine coverage, it was decided to not calculate separate cut-off values for the brand-specific analyses but instead rely on the values obtained for the analysis of any influenza vaccine. Additionally, for some age groups, the influenza vaccination coverage has been reported to be higher in the 2020/21 season as compared to the 2019/20 season. For the combinations of input parameters considered, the required number of influenza cases increased with increasing vaccination coverage, and the required number of influenza cases reported in Table 15 is expected to be lower than if it was based on the vaccination coverage of 2020/21, this is in line with preventing the cut-off from being too stringent.

The cut-offs will only be applied to the analysis of the IVE for any vaccine against any influenza strain. In case this analysis is performed for a certain setting and age group all the other analyses applying to this population will also be performed.

*Table 15. Vaccination coverage among control subjects and control:case ratio observed in the DRIVE data from the 2019/2020 season and the number of influenza cases required at a site to perform the site-specific analyses in the 2021/22 season.*

	Primary care			Hospital setting		
	6m-17yr	18-64yr	≥65yr	6m-17yr	18-64yr	≥65yr
Observed coverage among the controls	13%	10%	61%	5%	23%	56%
Control:case ratio	0.8	1.7	4.3	1.1	2.2	4.5
Number of influenza cases required for performing the analysis	155	102	24	155	45	18

## 16 Statistical analysis

### 16.1 Descriptive analyses not directly related to the IVE analyses

Several tables describing the data retrieved, epidemiological aspects, and characteristics of the vaccine distribution will be constructed using the data on all subjects which adhered to the in- and exclusion criteria (see [Section 9](#)). More particularly the following data will be reported:

- A table describing the site-specific dates of the first and last recorded swabs and the study period (Mock Report Table 2).
- A table describing which brands were observed to have been used in the different countries by age group (Mock Report Table 4).
- A table describing the influenza characteristics, including the distribution of the subtypes and lineages observed in the DRIVE dataset (Mock Report Table 5).

### 16.2 Site-specific analysis: test-negative design studies

#### 16.2.1 Attrition diagram

Records will be discarded from the primary and secondary objectives when:

- Subjects have missing information on the symptom onset date, swab date, outcome of interest, exposure of interest, age and sex (see [Sections 11-13](#)).
- Date of ILI/SARI onset is outside the study period (see [Section 7](#)). In case no study period could be defined for a specific site, no analyses will be performed for that site.
- Subjects do not adhere to the study in- and exclusion criteria (see [Section 9](#)).
- The ILI/SARI episode is not the first episode from recurrent episodes within the study period.
- Subjects that are potentially vaccinated (see [Section 11.2](#)).
- Subjects that are vaccinated ≤14 days prior to symptom onset (see [Section 11.1](#)).

For every TND study site, an attrition diagram will be created. The attrition diagram describes the number of records excluded from the statistical analysis at the central analysis level, by reason of exclusion. Note that for some sites the exclusion criteria are applied at the recruitment level or at the data transfer level (Table 7), which will not be captured in the attrition diagrams generated at the central analysis level. See Mock report Figures 1 and 2 for an example of an attrition diagram. In the case no

subjects are included for a specific site after the attrition diagram criteria have been applied, the data will not be considered in the IVE analyses.

### 16.2.2 Descriptive analysis

For every TND study site, visualizations based on the final data for analysis will be created including:

- Number of controls and laboratory-confirmed influenza infections (by type and by subtype/lineage) over time.
- Influenza positivity rate over time.
- Distribution of vaccine brands.
- Distribution of covariates among cases and controls.

Example visualizations are given in Mock Report Figures 3, 4 and 5. For every TND study site, the Web Annex will include a table based on the final data will be created with characteristics of cases and controls (overall and by vaccination status and brand). In case a descriptive table contains cells with a single subject, which might allow the identification of individuals, all table cells with a frequency equal to either the smallest or second smallest frequencies reported in the table will be left blank. Furthermore, the Web Annex will include tables describing SARS-CoV-2 positivity at the time of study entry and COVID-19 vaccination status.

### 16.2.3 Influenza vaccine effectiveness estimation

In case the number of influenza cases included in the pooled data set meets the criteria outlined in [Section 15.2](#) the IVE estimated will be calculated for each TND study.

For every TND study site, crude and confounder-adjusted IVE (any influenza vaccine, by brand, and by vaccine type) against laboratory-confirmed influenza (any, by influenza type, and by subtype/lineage) will be estimated stratified by age (6m-17yr, 18-64yr, ≥65yr), as:

$$VE = (1 - OR) \times 100\%,$$

where *OR* denotes the confounder-adjusted odds ratio, comparing the odds of vaccination among influenza-positive study participants to the odds of vaccination among influenza-negative study participants.

Confounder-adjusted IVE estimates will be derived from multivariable logistic regression models. For the primary and secondary objectives, a parsimonious set of confounders similar to the set of confounders used in Lane et al [7] and confirmed in the DRIVE Confounder Study (not yet published) will be used similarly. The parsimonious set of confounders will include sex, a smooth function of age, and a smooth function of the onset date. The selection of this set of confounders was based on a post-hoc analysis of the 2018/19 TND data in which no major differences in the results were observed when using either the parsimonious set of confounders or all available confounders. The smooth functions of age and onset date will be modeled using 10-dimensional cubic regression splines. The spline effects and coefficients included in the logistic regression model will be estimated using restricted maximum likelihood estimation (REML) which is also used to select an optimal smoothing parameter [8]. In case fewer than 10 unique age or onset date values are observed, the effect of age or onset date will be modeled using a linear function instead.

The analysis to estimate brand-specific IVE will account for the differences in approved indications (see Table 6), discarding from the analysis subjects for which the vaccine brand of interest is not indicated.

#### 16.2.4 Sensitivity analysis

The following sensitivity analysis will be conducted for the primary and secondary objectives:

Extended confounder-adjustment, presence of at least one chronic condition:

A sensitivity analysis will be performed, using an extended set of confounders including sex, a smooth function of age, a smooth function of the date of symptom onset, and presence of at least one chronic condition to allow further exploration of the impact of covariate adjustment on the IVE estimates. In the DRIVE confounder study, the presence of at least one chronic condition was found to be a confounder among children in hospital setting.

Extended confounder-adjustment, COVID-19 vaccination:

A sensitivity analysis will be performed, using an extended set of confounders including sex, a smooth function of age, a smooth function of the date of symptom onset, and COVID-19 vaccination to allow further exploration of the impact of covariate adjustment on the IVE estimates. Due to the possible positive correlation between vaccination probabilities for influenza and COVID-19, COVID-19 vaccination may be a confounder in IVE studies [9]. However the magnitude of confounding, particularly in populations with a higher coverage of COVID-19 vaccine, is unclear.

Time between ILI/SARI onset and swab:

Subjects will be excluded when the respiratory specimen was taken  $\geq 4$  days after ILI/SARI onset.

Estimation using Firth corrected estimation procedure

A sensitivity analysis in which the logistic regression model parameters are estimated using the Firth corrected maximum likelihood estimator [10]. This method allows the estimation of finite coefficients when the standard maximum likelihood estimator leads to infinite estimates, e.g. when a cell of the corresponding exposure—disease 2x2 table is zero.

Stratifying subjects by SARS-CoV-2 status:

A sensitivity analysis will be performed in which subjects are stratified by SARS-CoV-2 status at the time of ILI/SARI presentation. Due to the possible positive correlation between vaccination probabilities for influenza and COVID-19, the inclusion of SARS-CoV-2 controls may underestimate the IVE [9]. It is however likely that there will be insufficient co-infections or non-SARS-CoV-2 controls to perform these analyses.

### 16.3 Site-specific analysis: cohort study

#### 16.3.1 Attrition diagram

Only aggregated data will be shared on the DRIVE Central Analysis Environment. No attrition diagram at the central analysis level will be created.

#### 16.3.2 Descriptive analysis

The number of vaccinated and unvaccinated person-years and influenza cases by age group, overall and by vaccine, will be reported (Mock Report Table 7 and 12).

Visualizations (Mock Report Figure 6) based on the final data for analysis will be created, including:

- Number of laboratory-confirmed influenza infections (by type) over time.

- Number of controls and inpatient laboratory-confirmed influenza cases (by type) over time.
- Pie chart of the distribution of vaccine brands.
- Distribution of covariates among vaccinated and unvaccinated subjects for the cohort study.

The Web Annex will include a table based on the final data and describe the characteristics of the exposed and unexposed subjects. The table will be constructed with both laboratory-confirmed influenza and inpatient laboratory-confirmed influenza as the outcome of interest.

### 16.3.3 Influenza vaccine effectiveness estimation

Semi-crude (adjusted only for calendar time) and confounder-adjusted IVE (any influenza vaccine, by brand and by vaccine type) against any laboratory-confirmed influenza (any and by influenza type) and against any inpatient laboratory-confirmed influenza (any and by influenza type) will be estimated stratified by age (6m-17yr, 18-64yr, ≥65yr), as:

$$VE = (1 - IRR) \times 100\%,$$

where *IRR* denotes the confounder-adjusted incidence rate ratio, comparing the influenza incidence among the vaccinated subjects to the influenza incidence among the unvaccinated subjects.

Confounder-adjusted IVE estimates will be derived from multivariable Poisson regression models. For the primary and secondary objectives, a parsimonious set of confounders similar to the set of confounders used in Lane *et al* [7] and confirmed in the DRIVE Confounder Study (not yet published) will be used similarly. The parsimonious set of confounders will include sex, a smooth function of age, and a smooth function of the calendar week.

The analysis will be a complete case analysis, dropping records with missing information for the outcome, exposure of interest, or any of the covariates. The smooth functions of age and calendar week will be modeled by penalized cubic regression splines [8] estimated using restricted maximum likelihood for smoothness selection [11].

Example results tables are given in Mock Report Tables 12 to 14.

### 16.3.4 Sensitivity analysis

The following sensitivity analysis will be conducted:

#### Extended confounder-adjustment, at least one chronic condition:

A sensitivity analysis will be performed using an extended set of confounders including sex, a smooth function of age, a smooth function of the calendar week, and presence of at least one chronic condition to allow further exploration of the impact of covariate adjustment on the IVE estimates.

## 16.4 Pooled analysis

As this season NIID is a dedicated COVID-19 hospital all subjects will be infected with COVID-19. As all influenza infections are therefore expected to be co-infections, NIID will be excluded from the main analysis. An analysis with the NIID data included will be considered in a sensitivity analysis.



### 16.4.1 Descriptive analysis

The number of cases and controls and the proportion vaccinated will be shown by age group for the primary care and the hospital setting (Mock Report Table 6).

For the combined TND data, visualizations (Mock Report Figures 3, 4, and 5) based on the final data for analysis will be created by age group and setting, including:

- Vaccination coverage among study participants and distribution of vaccine brands.
- Number of controls and laboratory-confirmed influenza infections (by type and by subtype/lineage) over time.
- Influenza positivity rate over time

For the combined TND data, a table showing for each combination of setting, age group and exposure the total number of subjects, number of cases and controls overall and by vaccination status will be created (see Mock Report Tables 8 and 9); and tables based on the final data will be created with characteristics of cases and control by age group and setting). In addition, Mock Report Tables 11 and 12 will show the SARS-CoV-2 status and the COVID-19 vaccination status of at the time of study enrolment; and a table in the Web Annex will show availability of information on COVID-19 vaccine brand and date of vaccination by dose. In addition, tables showing characteristics of cases and controls by age group will be created and available from the Web Annex for 1) pooled data from primary care sites that perform swabbing at clinician's discretion (Iceland EL GP and UK RSCPRSC-OX), 2) pooled data from primary care sites that swab all patients or have systematic rules for swabbing (Austria MUV and Italy ISS).

### 16.4.2 Inclusion of influenza vaccine effectiveness estimates

Only estimates provided by the TND studies will be considered for obtaining pooled estimates stratified by age group (6m-17yr, 18-64yr, ≥65yr) and setting (primary care, hospital).

The population-based cohort study (THL, Finland) will not be considered for inclusion in the pooled analysis as potential issues due to differences between the study types, e.g., differences in case definitions, likely outweigh the limited added value.

### 16.4.3 Meta-analysis

Random-effects meta-analysis (RE MA) [12] will be used to pool the site-specific confounder-adjusted IVE estimates. This meta-analytical approach is preferred by DRIVE over a 1-stage pooling approach as both approaches have been shown to be equivalent [13-15]. The meta-analytical approach additionally allows to easily combine DRIVE IVE estimates with estimates obtained by other networks when appropriate.

Pooled estimates will be stratified by age group (6m-17yr, 18-64yr, ≥65yr) and setting (primary care, hospital). Random-effects meta-analysis will be performed on the log-transformed odds ratio (OR) estimates. Restricted maximum likelihood (REML) will be used to obtain the pooled (meta-analyzed) estimate (and 95% confidence intervals – CIs), as the REML estimator outperforms other RE MA estimators in terms of bias and statistical efficiency [16]. The modified Hartung-Knapp correction will be used to estimate the variance of the mean effect as it has been shown to outperform other methods in terms of the coverage of the 95% CIs in case of large between-study heterogeneity and varying study sizes [17]. The estimates (and 95% CIs) will then be back-transformed to obtain the pooled IVE estimate (and 95% CIs), expressed in %. In case site-specific estimates could not be obtained due to convergence issues they will be excluded from the meta-analysis and the corresponding descriptive tables.

An example forest plot is given in Mock Report Figure 7.

#### 16.4.4 Quantifying between-study heterogeneity

An indication for the heterogeneity among estimates from different study sites will be obtained by calculating  $I^2$  according to Higgins et al [18]. The  $I^2$  statistic is to be interpreted as the proportion of total variation in the estimates of treatment effect that is due to heterogeneity between studies. This measure will be used as a summary measure of the between-study heterogeneity and not for deciding on the appropriateness of pooling as the RE MA model accounts for different levels of between-study heterogeneity.

#### 16.4.5 Outlier and influence analysis, and exploring reasons for potential outlying studies

For every meta-analysis performed, the potential impact of outliers and influential estimates on the pooled estimate will be evaluated. Studentized deleted residuals  $r$  will be used to identify outliers in the meta-analysis. Site-specific IVE estimates will be considered outlying in the meta-analysis stage when  $|r| > 2.5$ , where  $|r|$  indicates the absolute value of the residual.

The standardized DFBETAs statistic will be used to identify influential estimates, examining the change in the averaged IVE from the random-effects model when excluding one site-specific estimate in turn. Site-specific estimates will be considered influential from meta-analysis when  $|DFBETAs| > 2/\sqrt{n}$ , where  $|DFBETAs|$  indicates the absolute value of the DFBETAs statistics and  $n$  is the number of effect estimates [19].

Site-specific estimates that are both outlying and influential will be excluded from meta-analysis and the reason for being outlying will be investigated.

#### 16.4.6 Sensitivity analysis

The following sensitivity analysis will be conducted:

##### Extended confounder-adjustment, presence of at least one chronic condition:

A sensitivity analysis will be performed using an extended set of confounders including sex, a smooth function of age, a smooth function of calendar time, and the presence of at least one chronic to allow further exploration of the impact of covariate adjustment on the IVE estimates. In the DRIVE confounder study, the presence of at least one chronic condition was found to be a confounder among children in hospital setting.

##### Extended confounder-adjustment, COVID-19 vaccination:

A sensitivity analysis will be performed, using an extended set of confounders including sex, a smooth function of age, a smooth function of the date of symptom onset, and COVID-19 vaccination to allow further exploration of the impact of covariate adjustment on the IVE estimates. Due to the possible positive correlation between vaccination probabilities for influenza and COVID-19, COVID-19 vaccination may be a confounder in IVE studies [9]. However the magnitude of confounding, particularly in populations with a higher coverage of COVID-19 vaccine, is unclear.

##### Stratifying subjects by SARS-CoV-2 status:

A sensitivity analysis will be performed in which subjects are stratified by SARS-CoV-2 status at the time of ILI/SARI presentation. Due to the possible positive correlation between vaccination probabilities for influenza and COVID-19, the inclusion of SARS-CoV-2 controls may underestimate the IVE [9]. It is however likely that there will be insufficient co-infections or non-SARS-CoV-2 controls to perform these analyses.

Time between ILI/SARI onset and swab:

Subjects will be excluded when the respiratory specimen was taken  $\geq 4$  days after ILI/SARI onset.

Outlying/influential studies:

Outlying/influential studies will be included in the meta-analysis.

Inclusion of NIID

The data from NIID will be included in the meta-analysis.

Including sites with no information on date of symptom onset:

A sensitivity analysis will be performed in which all sites that do not provide information on date of symptom onset (and for which the exclusion criterion time since symptom onset could thereof not be assessed) will be included (this is expected to be the case only for UK RCGPRSC-0X).

Site-specific estimates obtained using estimation method with Firth correction

As a sensitivity analysis, the IVE estimates obtained using the Firth corrected estimation procedure will be pooled using the two-stage estimation procedure.

## 17 Presentation of results

The presentation of the results is described in detail in the Mock Report.

## 18 Software

All data management and statistical analyses will be conducted in R 4.0.3. Git will be used for version control.

## 19 Limitations

Sample size requirements for brand-specific IVE depends on many unknown factors, including the influenza attack rates, vaccination coverage, distribution of brands, and (for the pooled estimates) the between-study heterogeneity. Given the ongoing COVID-19 pandemic, it is likely the number of influenza cases will be low in the 2021/22 season, and the threshold defined to perform the analyses may not be met. Additionally, due to the ongoing COVID-19 pandemic the influenza vaccination and healthcare seeking behavior/access patterns are likely to be significantly different compared to pre-pandemic seasons.

## 20 Quality control procedures

### 20.1 Documentation

The following study documents will be generated and are available upon request: Generic site-specific protocols, description of the minimum data requirements, season-specific protocols per study site, season-specific SAP, study summary sheets and codebook of variables within the analytical datasets, data quality report for each participating site.

### 20.2 Record retention

Documents that permit evaluation of the conduct of a study and the quality of the data will be retained for 5 years in accordance with Good Participatory Practice (GPP) guidelines. These documents will be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement between study partners.

The analytical datasets and data analysis scripts used to produce the site-specific IVE estimates will be retained at the participating study sites and made available for quality control upon request. The syntaxes used for the pooled analysis will be documented and made available for quality control upon request.

### 20.3 Data analysis and results

Quality control of R programs will include a review of the whole process of the results generation:

- Review of all analysis R programs;
- Review of R logs for errors, uninitialized variables, and warnings;
- Review of all tables, listings, and figures for completeness and correctness.

### 20.4 Monitoring of quality

The Quality Control and Audit Committee (QCAC) of DRIVE is composed of external quality control advisors (who may or may not represent consortium members). The QCAC will perform a 3-step assessment of the quality of the studies:

- Study conduct: whether the study was conducted in compliance with regulatory standards, the site protocol, and the local SOPs.
- Quality of the data: whether data collected from the field were processed in compliance with the DRIVE Data Management Plan (DMP).
- Quality of the analysis: whether the reported site-specific and pooled statistical analyses match with the SAP.

To evaluate these points, the QCAC will develop three checklists in agreement with DRIVE WP3 and P95. Based on the evaluation, the QCAC will provide recommendations to the DRIVE Steering Committee. The conclusion of QCAC will be described in a quality report and attached to the final study report.

## 21 Ethics considerations

### 21.1 Ethics Approval

Ethics committee clearance was required for yearly IVE assessment, with the exception of Finland THL, Italy ISS, and Spain FISABIO. Finland THL and Italy ISS sought the ethics committee clearance nonetheless, and Spain FISABIO obtained approval for the first year in 2009 (Table 16). The submissions to the ethics committee were mostly performed during summer, often in July, before the beginning of the influenza season.

Table 16. DRIVE 2021/22 study sites: ethics committees and date of approval.

Site	Country	Ethics committee	Date of approval
<b>MUV</b>	Austria	Ethics committee of the MUV	May 6, 2019
<b>THL</b>	Finland	Institutional review board of the National Institute for Health and Welfare, Finland	June 2, 2016
<b>I-REIVAC</b>	France	Comité de Protection des Personnes, Ile-de-France IV Ref CPP: 2013/44. IDRCB: 2013-A01204-41	May 27, 2021
<b>ELGP and ELHOSP</b>	Iceland	The National Bioethics Committee	September 1, 2020
<b>CIRI-IT BIVE</b>	Italy	Comitato Etico Regionale	Sept 27, 2021
<b>ISS</b>	Italy	Not required, but submitted to ISS Ethics committee for information	Nov 23, 2018
<b>NIID</b>	Romania	Bioethics committee of the NIID	Oct 15, 2021
<b>FISABIO</b>	Spain	CEIC de la Dirección General de Salud Pública y del Centro Superior de Investigación en Salud Pública	Dec 21, 2009
<b>GTPUH</b>	Spain	Comité de Ética de Investigación CLÍNICA (CEIC) del Hospital Universitari Germans Trias I Pujol	Jul 28, 2021 (same approval as La Paz )applicable)
<b>HUVH</b>	Spain	Comité Ético de Investigación Clínica del Hospital Universitari Vall d'Hebron	Oct 29, 2021
<b>LPUH</b>	Spain	Comité de Ética de la Investigación con medicamentos del Hospital Universitario La Paz	Jul 28, 2021
<b>SUH</b>	Spain	Comité de Ética de la Investigación con medicamentos del Área de Salud de Salamanca	Nov 2, 2021

### 21.2 Informed consent

At all sites except VHUH, GTPUH, and THL informed consent was required. For the THL register-based cohort study, informed consent was not required as the study makes use of secondary data from routine databases.

For the VHUH and GTPUH study, informed consent was not required as no interventions that fall outside the usual practice at both hospitals during the influenza season were needed.

## 22 References

- [1] Committee for Medicinal Products for Human Use. Guideline on Influenza Vaccines - Non-clinical and Clinical Module. EMA/CHMP/BWP/310834/2012. London: Eur Med Agency; 2016.
- [2] DRIVE consortium. D7.4 Setting up brand-specific influenza vaccine effectiveness studies in Europe – results of the pilot season 2017/18. Accessible from: [https://www.drive-eu.org/wp-content/uploads/2018/12/D7\\_4\\_Report-pilot-season-201718\\_v1.0.pdf](https://www.drive-eu.org/wp-content/uploads/2018/12/D7_4_Report-pilot-season-201718_v1.0.pdf). October 2018.
- [3] Flu News Europe. Intensity of influenza activity Week 5 2022. <https://flunewseurope.org/>. Week 5 2022.
- [4] ECDC. EU case definitions / Influenza including Influenza A(H1N1). <https://www.ecdc.europa.eu/en/surveillance-and-disease-data/eu-case-definitions>. Accessed 26 March 2020. <https://ecdc.europa.eu/en/surveillance-and-disease-data/eu-case-definitions>. Accessed: July 18, 2019.
- [5] de Lusignan S, Hoghton M, Rafi I. Flu vaccination by pharmacists leads to suboptimal medical records. *BMJ*. 2017;359:j5084.
- [6] NHS and PHE and Dept of Health & Social Care. The national flu immunisation programme 2019/20. <https://www.england.nhs.uk/wp-content/uploads/2019/03/annual-national-flu-programme-2019-to-2020-1.pdf>. Accessed: July 11, 2019.
- [7] Lane C, Carville KS, Pierse N, Kelly H. Seasonal influenza vaccine effectiveness estimates: Development of a parsimonious case test negative model using a causal approach. *Vaccine*. 2016;34:1070-6.
- [8] Wood S. Generalized additive models: an introduction with R. London: CRC Press; 2017.
- [9] Doll MK, Pettigrew SM, Ma J, Verma A. Effects of Confounding Bias in COVID-19 and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. *medRxiv*. 2021.
- [10] Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Statistics in medicine*. 2002;21:2409-19.
- [11] Marra G, Wood SN. Practical variable selection for generalized additive models. *Computational Statistics and Data Analysis* 2011:15.
- [12] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
- [13] Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? *PLoS One*. 2013;8:e60650.
- [14] Mathew T, Nordstrom K. Comparison of one-step and two-step meta-analysis models using individual patient data. *Biometrical Journal*. 2010;52:17.
- [15] Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. *PLoS One*. 2012;7:e46042.
- [16] Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. *Journal of Educational and Behavioral Statistics*. 2005;30.
- [17] Partlett C, Riley RD. Random effects meta-analysis: coverage performance of 95% confidence and prediction intervals following REML estimation. *Statistics in medicine*. 2017;36:301-17.
- [18] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21:1539-58.
- [19] Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. *Res Synth Methods*. 2010;1:112-25.

## 23 ANNEX 1: Study team

### DRIVE WP7

**Anke Stuurman.** MSc. Epidemiologist. P95, Leuven, Belgium.

**Jorne Biccler** PhD. Statistician. P95, Leuven, Belgium.

**Tom De Smedt.** Ir. DRIVE Research server system administrator. P95, Leuven, Belgium.

**Nick De Smedt.** Ir. DRIVE Research server system administrator back-up and data analyst. P95, Leuven, Belgium.

**Javier Díez-Domingo.** PhD. MD. Paediatrician. Head of the Vaccine Research Department of FISABIO-Public Health. (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana). Avenida de Cataluña, 21, 46020, Valencia. Principal investigator.

**Antonio Carmona Serrano.** PhD, Scientific Project Manager, FISABIO-Public Health

**Hanna Nohynek.** MD PhD Chief Physician. Deputy Head of Unit of Infectious Diseases Control and Vaccinations. Co-lead of Expert group on Influenza and Viral Acute Respiratory Infections. THL, Helsinki Finland.

**Ritva Syrjänen.** MD, PhD. Expert Scientist. Department of Public Health Solutions. THL, Tampere, Finland

**Paolo Bonanni.** MD. Full Professor of Hygiene and Public Health. Department of Health Sciences, University of Florence, Florence, Italy.

**Miriam Levi.** MD, PhD. Epidemiology Unit, Department of Prevention, Local Health Unit Tuscany Center, Florence, Italy.

**Roberto Bonaiuti.** ME. Biomedical Engineer. Department of Neurosciences, Psychology, Drug Research and Child Health - Section of Pharmacology and Toxicology, University of Florence, Florence, Italy

**Caterina Rizzo.** MD. Epidemiologist. Ospedale Pediatrico Bambino Gesù, Rome, Italy. National Focal Point for the Influenza and other respiratory viruses ECDC Program.

**Uy Hoang.** Dr. MBBS, MPH. Research Fellow. Department of Clinical and Experimental Medicine, University of Surrey, UK.

**Simon de Lusignan.** MBBS, MD. Professor of Primary Care & Clinical Informatics, Nuffield Department of Primary Care Health Sciences, University of Oxford. Director RCGP RSC, RCGP, London, UK.

**Stefania Bellino.** PhD. Statistician, Senior Researcher, Istituto Superiore di Sanità, Rome, Italy

**Christine Pereira.** Clinical study manager, INSERM, CIC 1417, Cochin Hospital, Paris, France

**Alexandre Descamps.** MD, Hospital practitioner, INSERM, CIC 1417, Cochin Hospital, Paris, France



## INDEPENDENT SCIENTIFIC COMMITTEE (ISC)

**Hector Izurieta**, MD, Food & Drug Administration, United States

**Liz Miller**, Prof, London School of Hygiene and Tropical Medicine, United Kingdom

**Mark Miller**, MD, National Institutes of Health, United States

**Marianne van der Sande**, MD, Prof, Institute of tropical medicine Antwerp, Belgium

**Stefania Salmaso**, MD, independent consultant; formerly National Institute of Health, Italy

## STUDY SITES

### Medical University Vienna (MUV), Austria

---

**Monika Redlberger-Fritz**. PhD, MD, Center of Virology, Medical University Vienna (MUV), Kinderspitalgasse 15, 1090 Vienna, Austria. Principal investigator, coordinating investigator and protocol author.

**Eva Geringer**. Center of Virology, Medical University Vienna (MUV), Kinderspitalgasse 15, 1090 Vienna, Austria. Co-investigator

### The National Institute for Health and Welfare (THL), Finland

---

**Hanna Nohynek**. MD PhD Chief Physician. Deputy Head of Unit of Infectious Diseases Control and Vaccinations. Co-lead of Expert group on Influenza and Viral Acute Respiratory Infections. National Institute for Health and Welfare (THL), Helsinki Finland. Principal Investigator of the study.

**Ulrike Baum**. MSc. Statistical researcher. Department of Health Security. THL, Helsinki, Finland. Principal statistician of the study.

**Ritva Syrjänen**. MD PhD Senior Researcher. Department of Public Health Solutions. THL, Tampere, Finland. Clinical trials and register study specialist of the study.

### Institut National de la Santé et de la Recherche Médicale (INSERM), French clinical research infrastructure network (F-CRIN) and Innovative clinical research network in vaccinology (I-REIVAC), France

---

**Odile Launay**. Prof. MD, PhD, INSERM, F-CRIN, I-REIVAC coordinator, Head of the Cochin Pasteur Clinical Investigation Center (CIC 1417), Cochin Hospital, Paris, France. Principal investigator.

**Claire Rekacewicz**. MD, INSERM, F-CRIN, I-REIVAC, Paris, France. Co-coordinator of the network.

**Zineb Lesieur**. PhD, INSERM, F-CRIN, I-REIVAC, Paris, France. Clinical study manager.

**Liem Binh Luong Nguyen**. MD, PhD, INSERM, F-CRIN, I-REIVAC, CIC 1417, Cochin Hospital, Paris, France. Hospital practitioner.

**Alexandre Descamps**. MD, MPH, INSERM, CIC 1417, Cochin Hospital, Paris, France. Hospital practitioner.



**Xavier Duval.** Prof. MD, PhD, INSERM, F-CRIN, I-REIVAC, IAME, Head of the Bichat Clinical Investigation Center (CIC 1425), Bichat Hospital, Paris, France. Co-investigator.

**Florence Galtier.** MD, INSERM, F-CRIN, I-REIVAC, CIC 1411, Montpellier Hospital, Montpellier, France. Co-investigator.

**Fabrice Lainé.** MD, INSERM, F-CRIN, I-REIVAC, CIC 1414, Rennes Hospital, Rennes, France. Co-investigator.

**Philippe Vanhems.** Prof. MD, PhD, INSERM, F-CRIN, I-REIVAC, Centre International de Recherche en Infectiologie (CIRI), Emerging Pathogens Laboratory, Head of the Infection Control and Epidemiology Department, Lyon Hospital, Lyon, France. Co-investigator.

**Christine Durier.** Senior researcher, INSERM SC10-US019, Villejuif, France. Principal statistician of the study.

**Rebecca Bauer.** INSERM SC10-US19, Villejuif, France. Statistician of the study.

**Yacine Saidi.** INSERM SC10-US19, Villejuif, France. Data manager.

#### **Istituto Superiore di Sanita (ISS), Italy**

---

**Maria Rita Castrucci. PhD.** Biologist. Head of the National Influenza Center at the Department of Infectious Diseases, ISS, Rome, Italy. Influenza virus expert.

**Simona Puzelli. PhD.** Biologist at the Department of Infectious Diseases, ISS, Rome, Italy. Influenza virus expert.

**Antonino Bella.** Statistician in the Department of Infectious Diseases of the National Institute of Health, ISS, Rome, Italy. Head of the Influenza Surveillance System (InfluNet). Statistician and data manager.

#### **Centro Interuniversitario di Ricerca sull'Influenza e sulle altre infezioni trasmissibili (CIRI-IT) Italian Hospital Network (BIVE), Italy**

---

**Andrea Orsi, MD.** IRCCS University Hospital San Martino, Genoa, Liguria Region. Principal Investigator in one of the participating hospitals and Coordinator of Italian Hospital Network (BIVE).

**Filippo Ansaldi, MD.** IRCCS University Hospital San Martino, Genoa, Liguria Region. Co-investigator.

**Caterina Rizzo, MD.** Innovation Unit and Clinical Paths, Directorate of Clinical Departments. Bambino Gesù Children's Hospital, Rome, Italy. Principal investigator.

**Christian Napoli, MD.** Department of medical-surgical sciences and translational medicine, "Sapienza" University of Rome, Lazio Region. Principal Investigator in one of the participating hospitals.

**Maria Chironna, Biologist.** Department of Biomedical science and medical Oncology of the University of Bari, Puglia Region. Principal Investigator in one of the participating hospitals.

**Giovanni Battista Orsi, MD.** Department of Public Health and Infectious Diseases, "Sapienza"

University of Rome, Lazio Region. Co-investigator.

**Ilaria Manini**, Biologist. Department of Molecular and Developmental Medicine of University of Siena-Italy, Tuscany Region. Principal Investigator in one of the participating hospitals.

**Emanuele Montomoli**, MSc. Department of Molecular and Developmental Medicine of University of Siena-Italy, Tuscany Region. Co-investigator.

**Giancarlo Icardi**, Prof. Director of IRCCS University Hospital San Martino, Genoa, Liguria Region.

**Donatella Panatto**, Prof. IRCCS University Hospital San Martino, Genoa, Liguria Region.

**Filippo Ansaldi**, Prof. IRCCS Ospedale Policlinico San Martino, Hygiene Unit, Genoa, Liguria Region.

**Silvana Castaldi**, Prof. Department of Biomedical Science for Health, University of Milan, Milan, Lombardy region.

**Elena Pariani**, Prof. Department of Biomedical Science for Health, University of Milan, Milan, Lombardy region.

#### **National Institute for Infectious Diseases “Prof. Dr. Matei Balș” (NIID), Romania**

---

**Anca Drăgănescu**, MD, PhD. Senior specialist paediatrics. Specialist infectious diseases. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Project manager and principal investigator – children.

**Daniela Pițigoi**, MD, PhD. Senior specialist epidemiology. Assoc. Prof. Epidemiology. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Technical project manager.

**Oana Săndulescu**, MD, PhD. Specialist infectious diseases. Assoc. Prof. infectious diseases National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Principal investigator – adults.

**Anuta Bilasco**, MD, Specialist Pediatrics. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Investigator.

**Prof. Dr. Adrian Streinu-Cercel** - MD, PhD, Senior specialist in Infectious Diseases. Study member.

**Victor Daniel Miron**, MD, PhDc in Infectious Diseases. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Study member.

**Bianca Enciu**. Resident physician, PhDc in infectious disease. Study member.

**Roxana Sandu**. Resident physician, PhDc in infectious diseases. Study member.

**Anca Streinu-Cercel**, MD, PhD. Senior Specialist in Infectious Diseases. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Investigator.

**Dragos Florea**, PhD. Molecular genetics. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Laboratory specialist.

**Ovidiu Vlaicu**. Molecular genetics. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Laboratory specialist.

**Dan Otelea**, PhD. Molecular genetics. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Laboratory specialist.

**Mihaela Fratila**. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Nurse.

**Elena Dafina**. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Nurse.

**Delia Azamfire**. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Nurse.

**Florenta Sandoi**. National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania. Management, HR.

#### **Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Spain**

---

**Javier Díez-Domingo**. PhD. MD. Paediatrician. Head of the Vaccine Research Department of FISABIO-Public Health. (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana). Avenida de Cataluña, 21, 46020, Valencia. Principal investigator.

**Ainara Mira-Iglesias**. PhD. Mathematician. Master’s degree in Biostatistics. Statistician in the Vaccine Research Department of FISABIO-Public Health. Avenida de Cataluña, 21, 46020, Valencia. Data analyst of the study.

**F. Xavier López-Labrador**. PhD. Virologist. Senior Laboratory Coordinator in the Genomics Department of FISABIO-Public Health. Avenida de Cataluña, 21, 46020, Valencia. Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. Laboratory Coordinator and Virologist of the study.

**Mario Carballido-Fernández**. PhD. MD. Hospital General Universitario de Castellón, Castellón, Spain. Universidad CEU Cardenal Herrera, Castellón, Spain. Principal investigator in one of the participating hospitals.

**Miguel Tortajada-Girbés**. PhD. MD. Hospital Universitario Doctor Peset, Valencia, Spain. Principal investigator in one of the participating hospitals.

**Juan Mollar-Maseres**. PhD. MD. Hospital Universitario y Politécnico La Fe, Valencia, Spain. Principal investigator in one of the participating hospitals.

**German Schwarz-Chavarri**. PhD. MD. Hospital General Universitario de Alicante, Alicante, Spain. Principal investigator in one of the participating hospitals.

## **Vall d'Hebron University Hospital (VHUH) & Hospital Universitari de Girona Doctor Josep Trueta (HJUT), Barcelona, Spain**

---

### ***Vall d'Hebron University Hospital***

**Magda Campins Martí.** MD,PhD. Head of the Department, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Principal investigator.

**José Ángel Rodrigo Pendás.** MD. Clinical researcher, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Co-Investigator and data analyst of the study.

**Sonia Uriona.** MD. Clinical researcher, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Data manager.

**Eva del Amo.** PhD. Research technician, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Study coordinator.

**Ingrid Carbones Fargas.** MSc, Research technician, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Data collection.

**Ricardo Gabriel Zules Oña.** MD. Clinical researcher, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Data collection.

**Irene Torrecilla Martínez.** MD. Clinical researcher, Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain. Data collection.

**Andrés Antón Pagarolas.** PhD. Head of Respiratory Viruses Unit, Microbiology Department, VHUH, Barcelona, Spain. Co-Investigator and virologist of the study.

**Cristina Andrés Vergés.** PhD. Laboratory researcher, Respiratory Viruses Unit, Microbiology Department, VHUH, Barcelona, Spain. Characterisation of influenza A and B viruses.

**Laia Pinos Tella** Me Preventive Medicine and Epidemiology Department, VHUH, Barcelona, Spain.

**Susana Otero Romero**

**Maria Rexach Fumaña** MD. Physician of Internal Medicine.

**Patricia Tejerina** Clinical analysis specialist at the clinical laboratory.

### ***Hospital Universitari de Girona Doctor Josep Trueta***

**Anna Oller Pérez-Hita** MD. Physician of Internal Medicine department.

**Montserrat Fusellas Masgrau** Nurse. Preventive Medicine and Epidemiology Department.

**Borja Guarch Ibáñez** MD. Physician of the Pediatric department.

**Antoni Castro Guardiola** MD. Head of the Internal Medicine department.

## **Hospital Universitario La Paz (LPUH), Madrid, Spain**

---

**Martín Quirós, Alejandro.** Physician. Internal Medicine. Specialist. PhD Faculty of Emergency department, Hospital Universitario La Paz Principal investigator. Recruiter. Data custodian.

**Romero Gómez, María Pilar,** Pharmacist. Microbiology specialist. PhD. Faculty of Microbiology Department. Hospital Universitario La Paz. Co-investigator. Influenza PCR processing.

**Martínez Virto, Ana María.** Physician. Family Medicine Specialist. PhD Faculty of Emergency department, Hospital Universitario La Paz. Co-investigator Recruiter.

**Muñoz del Val, Elena.** Physician. Family Medicine Specialist. Faculty of Emergency department, Hospital Universitario La Paz. Co-investigator Recruiter.

**García Rodríguez, Julio.** Physician. Microbiology specialist. PhD. Head of Microbiology Department. Hospital Universitario La Paz. Co-investigator. Influenza PCR processing.

**Romero Gallego-Acho, Paloma.** Emergency Medicine Department. Hospital Universitario La Paz

**Garcia Marín, Francisco.** Data manager. Hospital Universitario La Paz

**Rello Varona, Santiago.** Project manager. Fundación Investigación

**Narro Villanueva, José Luis.** Project manager. Fundación Investigación

**Torres Santos-Olmo, Rosario.** Chief of Emergency Medicine Department. Hospital Universitario La Paz.

**Rivera Núñez, Angélica.** Chief elect of Emergency Medicine Department. Hospital Universitario La Paz.

#### **Hospital Universitario Germans Trias i Pujol (GTPUH), Badalona, Spain**

---

**Guillermo Mena Pinilla.** MD, PhD. Physician at the Preventive Medicine and Epidemiology Department. Task: coordination of the study, vaccination and collection of clinical data.

**Irma Casas García.** MD, PhD. Physician at the Preventive Medicine and Epidemiology Department. Task: vaccination and coordination of the Control Infection Group.

**María Esteve Pardo.** MD, PhD. Head of the Preventive Medicine and Epidemiology Department. Task: vaccination and coordination of the Infectious Diseases Committee.

**Águeda Hernández Rodríguez.** PhD. Task: coordination of the laboratory tasks performed for the project.

**Cristina Casañ.** Physician at the Microbiology Department -Task: validation of the results from the detection of influenza viruses. Report of virological information for a database that will be shared with the collaborators working in the Preventive Medicine and Epidemiology Department.

**Elisabeth Bascuñana Prieto.** Laboratory technician, Microbiology department.

#### **Hospital Universitario de Salamanca (SUH), Salamanca, Spain**

---

**Amparo López Bernus**, MD, PhD. Internal Medicine Department, Infectious Unit. University Hospital Salamanca

**Ana Haro Perez**, MD, head of Preventive Medicine and Epidemiology Department. University Hospital Salamanca.

**Nieves Gutierrez Zufia**, MD, head of Respiratory Viruses Unit, Microbiology Department. University Hospital Salamanca.

**Cristina Carbonell**, MD, Internal Medicine Department, Infectious Unit. University Hospital Salamanca.

**Moncef Belhassen García**, MD, PhD. Internal Medicine Department, Infectious Unit. University Hospital Salamanca.

**Jose Angel Martín Oterino**, MD, PhD. Head of Internal Medicine Department . University Hospital Salamanca.

**Juan Luis Muñoz Bellido**, MD, PhD. Head of Microbiology Department. University Hospital Salamanca.

#### **Directorate of Health - Embætti landlæknis (EL), Iceland**

---

**Valtýr Stefánsson Thors**, MD, PhD. Paediatric Infectious Diseases. Children's Hospital Iceland, Landspítali University Hospital. Reykjavik, Iceland. Chief investigator.

**Asgeir Haraldsson**, Prof. Paediatric Immunology, Professor of Paediatrics, faculty chairman. Children's Hospital Iceland, Landspítali University Hospital. Reykjavik, Iceland & Reykjavík, Iceland.

**Arthúr Löve**, Prof. Head of virology department of Landspítali University Hospital Iceland.

**Kamilla Sigr. Josefsdóttir**, MD, Paed. Inf. Diseases, Centre for Health Security and Communicable Disease Control, Directorate of Health, Iceland. **Kristín L. Björnsdóttir**, Clinical nurse, Children's Hospital Iceland

#### **Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) & University of Oxford (OX), United Kingdom**

---

**Prof Simon de Lusignan**. Prof. Professor of Primary Care and Clinical Informatics. Chair in Health Care Management, University of Surrey, UK. University of Oxford, UK. Principal Investigator.

**Uy Hoang**. Dr. MBBS, MPH. Research Fellow. Department of Clinical and Experimental Medicine, University of Surrey, UK.

**Manasa Tripathy**, MSc, Department of Clinical and Experimental Medicine, University of Surrey, UK, Research Officer.

**Rachel Byford** Senior Database Developer. Department of Clinical and Experimental Medicine, University of Surrey, UK.

**Dr Mark Joy.** Senior Lecturer in Data Modelling and Population Health. Department of Clinical and Experimental Medicine, University of Surrey.

**Filipa Ferreira.** PhD Department of Clinical and Experimental Medicine, University of Surrey, UK. Project Manager

**Tristan Clark.** Associate Professor and Honorary Consultant in Infectious Diseases. NIHR Post-Doctoral Fellow. Academic Unit of Clinical and Experimental Sciences, University of Southampton.